8th Annual

CAR-ICR **Engineering A Disease-Free World**

August 29 - September 1, 2023 | Boston, MA

Accelerating the Future of Safe, Efficacious & Accessible Cell **Therapies by Harnessing Lessons Learned from Late-Stage** Treatments to Develop a Viable Cure for Oncology & Beyond



Nelly Viseux Senior Vice President, **Process & Analytical** Development & Clinical Manufacturing **2seventy bio**



Executive Director,

Worldwide Value &

Access Strategy, Cell

Therapy, Lymphoma

& Myeloma

Bristol Myers

John Rossi Vice President, Head of Translational Medicine CARGO Therapeutics



Laura McWright Deputy Director, Seamless Care Models Group **Centers** for **Medicare & Medicaid Services**

Stephan Grupp Director, Cancer Immunotherapy & **Cell Therapy Children's Hospital** of Philadelphia



Peter Marks Director, Center for **Biologics Evaluation** & Research FDA

Frank Neumann Senior Vice President & Global Head of Kite, A Gilead Company

Jennifer Brogdon

Immuno-Oncology & **Novartis Institutes** of BioMedical

Gang Zeng **T-Cure Biosciences**

ansonwad

PARTNERSHIP **OPPORTUNITITES**

PRICING & DISCOUNTS





www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com 📊 Cell Immunotherapy 🏏 @CAR_TCell 🕑 Preview the Event

REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING **DIVERSITY AT** CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

Welcome to the 8th CAR-TCR Summit

A Letter from our Program Director

To Our Global CAR-TCR Community,

Last year was momentous for the cell therapy field! As Emily Whithead celebrated 10 years being cancer free, it was the year that CAR-T therapies became curative. This decade of success has triggered the development of next generation approaches including multiplexed editing, armoring, in vivo engineering, and more, each promising to revolutionize the cell therapy field!

The 8th CAR-TCR Summit will be returning to Boston in August 2023, as the industry's trusted, definitive, end-to-end forum for the global network of cell therapy drug developers. Boasting all key updates across CARs, TCRs and a variety of cell types, this meeting is your unmissable opportunity to collaborate and network with industry pioneers as the focus moves further towards conquering solid tumors and indications beyond oncology.

So, whether you specialize in **discovery**, translation, early-stage clinical strategy, clinical operations, manufacturing, CMC, analytics, supply chain, logistics, commercialization, or market access, you can be confident that this forum will address your issues front of mind!

I look forward to welcoming your team to Boston this August to herald in a new frontier of medical marvels that can really cure the uncurable.



In Proud Partnership with:

Master effective delivery, specificity, and durability with in vivo CAR-T

with Capstan Therapeutics, Sana Biotechnology, Umoja Biopharma

Uncover the blockbuster potential for cell therapies to have curative

potential in indications beyond oncology including autoimmune

Optimize cell therapy manufacturing through implementing

Therapeutics, Kyverna Therapeutics and more.

diseases with Cabaletta Bio, Cartesian Therapeutics, iCell Gene

innovative equipment, reducing production timelines, and retaining

skilled staff with 2seventy bio, Bristol Myers Squibb, Immatics,

engineering, revolutionizing the way we manufacture cell therapies

5 Reasons to Attend this Year

Stanford University and more.

and more.



REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP **OPPORTUNITITES**

PRICING & DISCOUNTS



Elevate your CMC and analytical strategy, overcoming challenges

preventing effective demonstration of efficacy, safety, and potency with Alliance for Regenerative Medicine, Mustang Bio, Takeda and more.



Uncover how leaders in the field have successfully developed effective pricing strategies and launch plans for their approved cell therapies with Atara Biotherapeutics, Kite Pharma, Legend Biotechnology, Novartis and more.



ansonwad

More than Just a Meeting

Drinks Receptions

In addition to the unrivalled scientific content, in the form of presentations, panels and roundtable discussions, we also organize a variety of extra experiences that you can join on-site at the 8th CAR-TCR Summit. Get involved to make the most of your time with us!

 Image: Constant state s

N

PARTNERING

One-on-One

Partnering

August 29 - September 1, 2023

Boston, MA

Tech Slam

NEW

FOR 2023

Session

emily whitehead

Foundation

Emily Whitehead Foundation Run

ARTCR

You can also look forward to getting involved with ambassador receptions, private lunches, off-site visits, yoga classes, DE&I sessions and more!

Breakfast

Briefings

nansonwade REGISTER

PARTNERS

OPPORTUNITITES PRICING & DISCOUNTS

 \bigcirc



CAR-TCR

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

A MEETING SPEAKERS

REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST

AGENDA AT A GLANCE

August 29 – September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

hansonwade

NOW



August 29 - September 1, 2023 Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

REGISTER

NOW

hansonwade

CAR-TCR



August 29 - September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

hansonwad

NOW



August 29 - September 1, 2023 Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

CAR-TCR

hansonwad

NOW



www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com in Cell Immunotherapy 🔰 @CAR_TCell 🕑 Preview the Event

7

August 29 - September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

hansonwade

NOW



August 29 - September 1, 2023 Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

CAR-TCR

hansonwade

NOW



www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com in Cell Immunotherapy 🔰 @CAR_TCell 🕑 Preview the Event

9

August 29 – September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150



www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com in Cell Immunotherapy 🔰 @CAR_TCell 🕑 Preview the Event 10

hansonwade

August 29 - September 1, 2023 Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

CAR-TCR

hansonwad

NOW



August 29 - September 1, 2023 Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

CAR-TCR

hansonwade

NOW



August 29 - September 1, 2023 Boston, MA CAR-T<u>CR</u> REGISTER IN ADVANCE TO SAVE \$150



CAR-TCR Advisory Board

August 29 - September 1, 2023 CAR-TCR Boston, MA



WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A

GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING **DIVERSITY AT** CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2



Joanna Brewer Chief Scientific Officer Adaptimmune



Chief Scientific President & Chief Officer **Executive Officer Adicet Bio Biotherapeutics**

Atara



Adrian Bot Chief Scientific Officer & Executive Vice President, R&D Capstan Therapeutics



Stephan Grupp Director, Cancer Immunotherapy & **Cell Therapy Children's Hospital** of Philadelphia



PARTNERSHIP **OPPORTUNITITES**

PRICING & DISCOUNTS



August 29 – September 1, 2023 CAR-TCR Boston, MA

Agenda at a Glance

REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING

DIVERSITY AT CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE

DAY 3

PARTNERS

PARTNERSHIP **OPPORTUNITITES**

PRICING &

DISCOUNTS

 \bigcirc

NOW

н

		onferen day, Aug	ice Day gust 29			۷		iferen esday			0						nce D , Augu								nce D eptem		
	Reg	istration	Open				Ор	ening	Remo	arks					Ор	ening	g Remo	arks					Ор	ening	g Remo	arks	
					Fire	eside	Chat	& Piei	nary I	Prese	entati	ons	oı	pening	g Pane	l & Pl	enary	Prese	entati	ons			Plena	ry Pr	esento	ation	5
ws	ws	ws	101	FD		Мо	orning	Break	& Ne	etworl	king			٨	Aorning	g Bred	ak & Te	ech Slo	nm			M	orning	g Bred	ak & Te	ch Slo	т
					A	в	с	D	E	F	G	н	A	в	c	D	E	F	G	н	A	в	с	D	E	F	G
	L	unch Bre	eak					Lunch	Breal	k						Lunch	n Breal	k						Luncl	n Breal	C	

Plenary Presentations D WS FD WS WS 101 Afternoon Break & Tech Slam Afternoon Break & Poster Session **Closing Remarks** Close of Conference **C-Level Think Tank** Α н Δ В С D E G н R С D E G **Diversity at CAR-TCR** Welcome Reception Drinks Reception End of Conference Day 2 C – Early-Stage Clinical Strategy G – Supply Chain & Logistics H – Commercialization & **B** – Translation E – Manufacturing F - CMC & Analytics A – Discovery **D** – Clinical Operations **Market Access**





PRE-CONFERENCE DAY OVERVIEW

Tuesday, August 29

Use the buttons to below to navigate straight to your preferred pre-conference day!



WORKSHOP DAY | 9.00 - 4.00

- Extending the reach of cell therapies with *in vivo* therapies and moving beyond oncology
- Streamlining therapeutic development, discussing combination strategies and key regulatory considerations
- Hoving towards smarter manufacturing, discussing automation and decentralized manufacturing

BOOTCAMP DAY | 9.00 - 4.00

- Reviewing the CAR-TCR fundamentals and previous success
- Discussing gene engineering, cell types and solid tumors
- → Exploring *in vivo* CAR-T and indications beyond oncology

FOCUS DAY | 9.00 - 4.00

- → Reviewing mechanisms of resistance
- Deveraging innate immune cells for success in overcoming the tumor microenvironment
- Developing next-gen CAR-T and TIL therapies to overcome mechanisms of resistance

C-LEVEL THINK TANK | 1.00 - 4.00

- This exciting addition to the program is an exclusive free-to-attend session. Top C-level executives will gather in a closed room panel to discuss the most pressing challenges facing the CAR-TCR field and share thought leadership on how to drive the cell therapy field into a new era of more accessible 'curative' therapies. If you are interested in getting involved, please get in touch.
- Eed by Adrian Bot, CSO, Capstan Therapeutics and Peggy Sotiropoulou, CSO, T-knife Therapeutics

DISCUSSING DIVERSITY AT CAR-TCR | 4.00 - 6.00

Improving diversity, equity, and inclusion in the workplace and clinical trials

WELCOME RECEPTION | 5.30 - 6.30

Reunite with old friends and meet new colleagues before the main event begins

REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

> CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES

> PRICING & DISCOUNTS



ansonwad

Workshop Day | Tuesday, August 29

August 29 – September 1, 2023 Boston, MA CAR-TCR



Workshop A			
	Workshop B	Workshop C	WELCOME
9.00 Extending the Reach of CAR-T Cell Therapies Beyond Oncology to Autoimmune Diseases Long-term studies have displayed the curative potential of CAR-T	9.00 Leveraging Combination Strategies to Optimize the Efficacy of Cell Therapies Cell therapies have revolutionized the therapeutic landscape	9.00 A CAR-T Cell Manufacturing Life-Cycle Approach for Dramatic Reduction in Cost and Time Towards Making Cell Therapies More Affordable Globally	MORE THAN JU A MEETING
therapies to treat cancer. However, the number of potential targets amenable for CAR-T is expanding rapidly, meaning the success of this approach in oncology could be further translated to treating other diseases.	for heme malignancies; however, resistance and relapse remain limitations. Rational combined modality treatments are regarded as a promising strategy to further unlock the anti-tumor potential. Attend to:	A dramatic reduction in the cost and time for CAR-T cell manufacturing necessitates a manufacturing life-cycle approach where each of the steps needs innovation, from apheresis to product release.	SPEAKERS
Attend to: • Understand the potential of CAR-T for autoimmune diseases • Explore the key differences between developing CAR-T for	 Overcome the challenges and limitations of monotherapy with combinations Review different combination strategies with promise: viral 	Attend to: Understand the CAR-T cell manufacturing life-cycle approach with next generation innovations 	AGENDA AT A GLANCE
oncology versus non-oncology indications Identify key regulatory hurdles to overcome	therapeutics, small molecules and innovative delivery strategiesEnable success in solid tumors with combination therapies	 Understand the next generation viral vector manufacturing for CAR-T cells Understand the technology for dramatic reduction in timelines for 	WORKSHOP DA
Samik Basu, Chief Scientific Officer, Cabaletta Bio Chris Jewell, Chief Scientific Officer, Cartesian Therapeutics Greg Deener, Chief Executive Officer, iCell Gene Therapeutics	Francesca Barone, Chief Scientific Officer, Candel Therapeutics Daniel Corey, Founder & Chief Executive Officer, CERo Therapeutics	CAR-T cells manufacturing Bikash Verma, Chief Executive Officer, MedTherapy Biotech	FOCUS DAY
areg beener, chief Executive Officer, icen Gene merupeaucs	Steven Katz, Chief Medical Officer, TriSalus Life Science	Vladimir Slepushkin, Chief Technology Officer, MedTherapy Biotech	DISCUSSING DIVERSITY AT CAR-TCR
	12.00 Lunch Break		
Workshop D	Workshop E	Workshop F	CONFERENCE DAY 1
1.00 Moving Beyond <i>Ex Vivo</i> : The Promise of <i>In Vivo</i> Engineered Cell Therapies	1.00 Outlining Key Regulatory Considerations for IND & BLA Approval of Novel Cell Therapies	1.00 Implementing Technological Innovations to Enable Automated Cell Therapy Manufacturing	
Although <i>ex vivo</i> approaches have produced some remarkable clinical responses and approvals, they have several disadvantages including production time, cost, manufacturing delay and more.	Although there is regulatory guidance for the development of cell and gene therapies, emerging novel ideas mean that the cell therapy landscape is constantly evolving. This is also mirrored by an	Automated cell therapy manufacturing will reduce manual intervention, improve product quality, and reduce costs. However, leaps and bounds in terms of innovation are still required to make this a reality for all.	CONFERENCE DAY 2
<i>In vivo</i> CAR-T approaches aim to tackle these challenges head on, having promise as the future of cell therapy.	evolving regulatory landscape. Attend to:	Attend to: Discuss the value proposition for moving towards automated, closed system cell therapy manufacturing 	CONFERENCE DAY 3
 Attend to: Discuss next steps to streamline preclinical and clinical development to fast-track <i>in vivo</i> therapies into the clinic Develop safe and effective delivery mechanisms: viral versus non- 	 Define the best approach to submitting filings with regulatory bodies (IND through to BLA) Understand how to best introduce novel ideas and work out flexible plans with regulators 	 Understand the potential these processes have to improve quality, throughput, and cost Develop new bioreactor and sensor technologies to enable automated manufacturing processes 	PARTNERS
 Unlock the <i>in vivo</i> potential: the potential for treating indications beyond oncology 	 Share experience and advice regarding key pain points Brian Kevany, Chief Technical Officer & Head of Research, Abeona 	Ohad Karnieli, Founder & Chief Executive Officer, Adva Biotechnology Krishnendu Roy, Director, NSF ERC for Cell Manufacturing	PARTNERSHI
Michael Rosenzweig, Executive Vice President, Strategy & Product Development, Capstan Therapeutics	Therapeutics Omer Butt, Vice President, Regulatory Affairs, Cytolmmune Therapeutics	Technologies & Marcus Center for Therapeutic Cell Characterization & Manufacturing, Georgia Institute of Technology	PRICING &
	Alison Holzer-Speed, Senior Director, Regulatory Affairs, Kite, A	Bruce Levine , Barbara & Edward Netter Professor in Cancer Gene Therapy & Center for Cellular Immunotherapies Director of	DISCOUNTS
Jim Edinger, Vice President, Preclinical Science, Mustang Bio		Technology Innovation, University of Pennsylvania	
Kutlu Elpek, Senior Director, T-Cell Therapeutics, Research Lead, In	Gilead Company	······································	
	Gilead Company 4.00 End of Workshop Day	,	
Kutlu Elpek, Senior Director, T-Cell Therapeutics, Research Lead, In			

hansonwade

REGISTER

Bootcamp Day | Tuesday, August 29

Reviewing CAR & TCR Fundamentals





Focus Day | Tuesday, August 29

8.00

8.55

9.00

9.30

11.00

11.30

1.00



REGISTER IN ADVANCE TO SAVE \$150

August 29 – September 1, 2023 Boston MA Overcoming Mechanisms of Resistance & the Solid Tumor Microenvironment **Registration Open & Coffee Networking** 1.30 **Targeting Solid Tumors with SMART CAR-T by Overcoming Suppressive Tumor Microenvironment Shon Green** Vice President, Nonclinical • Overcoming the suppressive tumor microenvironment, a **Chair's Opening Remarks** Development major obstacle for CAR-T cell therapy in solid tumors Adicet Bio • Converting negative signaling of suppressive TME LJ Shen Senior Vice President, Head of molecules into a positive signal to promote T-cell **Reviewing Mechanisms of Resistance** R&D proliferations and survival **Gracell Biotechnologies** Revealing preclinical data showing SMART CAR-T **Reviewing the Intrinsic Mechanisms of Resistance to Cell** cells have improved resistance to suppressive tumor Therapy microenvironment and superior efficacy in immune cold CAR-T cells: lack of expression, lack of persistence, tumor models Sid Kerkar exhaustion Sharing updates on ongoing clinical testing Vice President, R&D Tumor microenvironment: impaired trafficking, EXUMA Biotechnology metabolism, immune suppression Tumor cells: loss of target antigen, expression of inhibitory ligands, resistance to immune killing 2.00 **Overcoming the Challenges of CAR-T in Solid Tumors** Hong Ma John Rossi Reviewing CAR-T proof-of-concept data in solid tumors Senior Vice President, Clinical Vice President. Head of **Roundtable Discussion: Discussing Mechanisms of** · Developing next-gen technology to improve persistence Translational Medicine Development **Resistance & How to Overcome Them** and homing of CAR-T **CARGO Therapeutics CARsgen Therapeutics** · Driving improvements in the delivery of CAR-T • What mechanisms of resistance are the most problematic? **Renaud Vaillant** How can we overcome mechanisms of resistance and Founder & Chief Executive develop effective cell-based therapies? Officer Alaya.bio 2.30 **Afternoon Break & Networkina** 10.30 Morning Break & Networking **Developing Next-Generation TIL Therapies to Overcome Mechanisms Resistance** Leveraging Innate Immune Cells to Overcome the Tumor Microenvironment **Overcoming Resistance & the Tumor Microenvironment** 3.00 **Next-Gen TIL: Counteracting the Solid Tumor** with CAR-Macrophage Therapies Microenvironment · Pioneering next-generation cell therapies to cure difficult-Sumiti Jain Targeting immune checkpoint targets using gene editing **Michelle Simpson Abelson** to-treat cancers Vice President, Head of R&D Executive Director, Research Developing tethered cytokine approaches to increase TIL DATA - Developing novel mechanisms to enhance immune cell Inceptor Bio **Iovance Biotherapeutics** persistence post-infusion performance in the solid tumor microenvironment Presenting new data on Inceptor Bio's CAR-macrophage product Enhancing tumor-specific immunity through enrichment and selection Leveraging NKT Cells to Tackle the Tumor Microenvironment Developing CAR-NKT therapies to tackle tumor **Jason Damiano** microenvironment challenges Chief Scientific Officer · Leveraging multiple killing mechanisms to overcome cancer Appia Bio heterogeneity challenges 3.30 **Developing Gene-Edited TIL Cell Therapy Products to** Sharing pre-clinical data **Revolutionize the Treatment of Solid Tumors** Karrie Wona Systematically identifying targets that have the potential Senior Director, Head of Cell 12.00 Lunch Break to improve T-cell function in the tumor microenvironment Therapy Developing a pipeline of gene-edited TIL cell products **Developing Next-Generation CAR-T Therapies to Overcome KSQ Therapeutics** Demonstrating improved tumor-killing abilities in **Mechanisms of Resistance** preclincial tumor models Strategies to Deliver Best-in-Class Engineered CAR-T Cell Products to Overcome Resistance & Address Barriers to Patient Access 4.00 **End of Focus Day John Rossi** Multiple autologous CAR-T cell products are now commercially Vice President, Head of approved in the setting of NHL and MM; however, many **Translational Medicine** patients still relapse 4.10 **Discussing Diversity at CAR-TCR** • Leveraging scientific data and clinical experience to direct **CARGO Therapeutics** development of next-gen engineered cellular therapy products Discussing known resistance mechanisms and strategies to 5.30 Welcome Reception overcome resistance



 (\rightarrow) REGISTER NOW

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING **DIVERSITY AT** CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE

PARTNERSHIP **OPPORTUNITITES**

- PRICING & DISCOUNTS
- DAY 3

PARTNERS

REGISTER IN ADVANCE TO August 29 - September 1, 2023 Discussing Diversity at CAR-TCR | Tuesday, August 29 CAR-TCR **SAVE \$150** Boston, MA **Diversity, Equity & Inclusion in Cell Therapy Biopharma** WELCOME End of Workshop Day, Bootcamp Day, Focus Day & C-Level Think Tank 4.00 MORE THAN JUST A MEETING **Greaory Fiore Chair's Opening Remarks Board Member** 4.10 **SPEAKERS Eterna Therapeutics** AGENDA AT A GLANCE Strengthening Clinical Trial Diversity to Understand Efficacy Across Population Groups 4.15 **Adalynn Harris** President & Chief Executive Distinguishing why safety and efficacy of group treatment analyses are important for trial interpretation WORKSHOP DAY Officer · Understanding and overcoming barriers to patient accrual of historically underrepresented groups in the US **Equity Bridge** Preparing for true global inclusion: cancer burden and clinical research needs of sub-Saharan Africa FOCUS DAY DISCUSSING **Adalynn Harris DIVERSITY AT** President & Chief Executive CAR-TCR Officer **Equity Bridge** Panel Discussion: Fostering Diversity in Cell Therapy Clinical Trials 4.45 CONFERENCE How do we motivate clinical trial sites to recruit diverse patient populations? DAY1 • What can we do to increase enrollment and improve retention? **Albeena Nisar** How do we overcome patient mistrust and lack of understanding of clinical trials? Scientific Officer & Head CONFERENCE of Clinical Manufacturing, DAY 2 CAR-T Cell Therapy Center

Welcome Reception 5.30

Reunite with old friends and meet new colleagues before the main event begins.



Tata Memorial Centre

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP **OPPORTUNITITES**

PRICING & DISCOUNTS



hansonwade

DAY 1 OVERVIEW

Wednesday, August 30

Use the buttons to below to navigate straight to your favourite track!



MORNING PLENARY SESSIONS

Autologous versus allogeneic versus *in vivo*: which will prevail?

DISCOVERY TRACK

- → Discovering and testing TCRs for the next generation of cell therapies
- Developing and translating a robust early TCR pipeline
- → Evaluating and improving CAR design to increase antitumor efficacy

EARLY-STAGE CLINICAL STRATEGY TRACK

- → Preparing for IND submission to the FDA
- → Sharing early-stage clinical results and strategy

MANUFACTURING TRACK

- Optimizing manufacturing process and quality control
- \bigcirc Reducing vein-to-vein time to improve speed to patient
- Building and optimizing your own manufacturing facility

SUPPLY CHAIN & LOGISTICS TRACK

- \bigcirc Transitioning from clinical to commercial supply volumes
- → Implementing effective risk mitigation strategies for a robust supply chain
- ⊖ Interfacing effectively with internal and external stakeholders

DRINK'S RECEPTION

⊖ Join your peers for some informal networking, drinks, and nibbles.

TRANSLATION TRACK

- → Translating therapies for hard-to-treat indications
- ⊖ Identifying clinical biomarkers to predict and assess response
- ⊖ Enhancing cell therapy persistence and reducing exhaustion

CLINICAL OPERATIONS TRACK

- \bigcirc Establishing new clinical programs, teams, and operations
- → Managing complex cell therapy clinical trials
- ⊖ Overcoming challenges in patient recruitment, retention & follow up

CMC & ANALYTICS TRACK

- ⊖ Optimizing characterization to better predict cellular attributes
- Overlapping characterization strategies for ancillary materials & cell product
- ⊖ Discussing regulatory guidance to ensure CMC regulatory compliance

COMMERCIALIZATION & MARKET ACCESS TRACK

- ⊖ Gaining insight into the payers' perspective
- \bigcirc Exploring strategies for pricing and reimbursement success
- Developing a strategy to reach markets beyond the United States

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES


> PRICING & DISCOUNTS



hansonwade

August 29 - September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150





23

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

							COMMERCIALIZATION & MARKET ACCESS TRACK	
MORNING SESSIONS	:	POST-LUNC	H SESSIONS	:		AFTERNOON SE	SSIONS	WELCOME
Chair: Luke Pase, Chief Technology Officer, Anocca		Chair: Luke Pase , Chief Te	echnology Officer, Anocca		Chair:	Luke Pase , Chief Techno	ology Officer, Anocca	MORE THAN JUST A MEETING
Discovering & Testing TCRs for the Next Generation Cell Therapies	of	Developing & Translating o	a Robust Early TCR Pipeline	e	Evalı	ating & Improving CAR Anti-Tumor Eff		SPEAKERS
11.00 Fast & Reliable Discovery of Safe TCRs with Tunable Antigen Specificity	• Le	TCRs for Cancer Therapy & everaging iNKT cell propertie			Potency Enh	-	ficacy of Cell Therapeutics	AGENDA AT A GLANCE
 Describing variational synthesis (ability to create high quality lil incorporating patient repertoire/HLA/neo-antigen informatio Leveraging benefits of variational synthesis (incorporating benefits of variational synthesis and a single synthesis) 	n) • Er ng fu	llogeneic format nabling high-throughput rap Inctional TCRs via our proprie	etary TrxTM platform		effective a Developing 	nti-cancer cell therapies novel receptor architectu	oproaches to drive safe and res that enable dual antigen	WORKSHOP DAY
 benefits of stochastic synthesis with cutting edge ML pip Sharing results of our eTCR discovery pipeline for patient where traditional TCR discovery approaches have failed 	is m	eveloping a robust and scale anufacturing process hi Chantzoura , Director, Disc		.1	recognitior	and killing a suite of potency enhance	uisitely sensitive tumor cell	FOCUS DAY
oncology setting Cameron Gardner, Director, Research Development, JUR/ 11.30 Rapid Engineering of Soluble TCRs for Enhanced	A Bio 2.00 Mic	D Harnessing the Power of t robioreactor to Address Ce	the Mobius® Breez		receptors, i signaling, f Steve Shame	nducible cytokines, and co or driving highly potent an ah , Senior Vice President, C	mplementary costimulatory ti-tumor responses	DISCUSSING DIVERSITY AT CAR-TCR
 Affinity via a High-Throughput Yeast-Based Platform Validating the expression and binding of yeast-producer soluble TCRs to their cognate peptide-HLAs Optimizing the affinity of two literature TCRs through selections of large yeast libraries 	۰ Le d dı ۰ In	Emization Challenges everaging a 2 mL automated evelopment (PD) across cell t nplementing a small-scale p ell therapy process understar emonstrating the Mobius® E	therapy unit operations erfusion technology to impr nding	ove	Discovery aHighlightir	AR Concept to Cure: Ch nd Solutions for Clinical ng the process of CAR dis	Success	CONFERENCE DAY 1 CONFERENCE
 Expressing and characterizing optimized TCR variants ir high-throughput platform Evaluating the specificity and T cell killing activity of optimized TCR leads as CD3 bispecifics 	na to (C Kar	a Levine, Senior R&D Managine Transition of the senior of the senior R&D Managine Senior R&D Managine Sigma	ol critical process parameter	S	 Developing streamline successful Sharing be 	g solutions to navigate co our client's CAR discover programs and unique ap enefits of partnering with	ommon pitfalls and ry, sharing case studies of plications Charles River, navigating	DAY 2 CONFERENCE DAY 3
 Garrett Rappazzo, Scientist, Platform Technologies, Adin 12.00 Panel Discussion: De-Risking TCRs to Ensure their Se How do we pick the right target? 	afety of Q	D Mediating Successful Disc Quality TCR Integrating functional HTS with	-	tion	therapeut	set , Senior Group Leader		PARTNERS
 How do we identify the right parental TCR? How should we best screen for cross-reactivity and alloreactivity? 	a • M	ccelerate TCR and cognate p lining safe, tumor-reactive, s	p-HLA discovery	ng	5.00 Evolut	ion of Solid Tumor-Targo Iteral Architectures	eting CAR-T cells from	PARTNERSHIP OPPORTUNITITES
Leah Sibener, Co-Founder, Vice President of Therapeutic Discovery, 3T Biosciences Reagan Jarvis, Co-Founder & Chief Executive Officer, And Gang Zeng, Pesident & Chief Executive Officer, T-Cure	• Le ai	ptimal TCR affinities everaging reductionist <i>in vitr</i> nd optimal T-cell priming in 1 wn Kubli , Director, Cell There	manufacturing		 Summariz patients w Optimizing 	ing a phase 1 clinical trial ith head and neck cance g novel lateral CAR platfo		PRICING & DISCOUNTS
Biosciences Panel Moderator: Gavin MacBoath Chief Everytive Officer TScan Therape	utice 3.00	0 Afternoon Break & Tech S	Slam			tumor model systems , Chief Scientific Officer, I	Leucid Bio	
Gavin MacBeath, Chief Executive Officer, TScan Therape	Hea	r the latest innovations that apy development!		II	5.30 Drink's Join your pe	-	working, drinks & nibbles.	
23 www.car-tcr-summit.com Tel: +1 617 45	5 4188 Email:	info@hansonwade.co	m in Cell Immunothe	erapy 🈏	@CAR_TCe	ell 🕑 Preview the I	Event	

24



REGISTER IN ADVANCE TO SAVE \$150

	-		0					· · · · · · · · · · · · · · · · · · ·	
DISCOVERY TRACK	TRANSLATION TRACK	EARLY-STAGE CLINIC STRATEGY TRACK	AL CLINICAL OPERATIONS TRACK	MANUFACTURING TRACK	CMC & ANA TRAC		SUPPLY CHAIN & LOGISTICS TRACK	COMMERCIALIZATION & MARKET ACCESS TRACK	
MOD	NING SESSIONS	:	POST-LUNCI		:		AFTERNOON SE	SSIONS	WELCOME
	non Dahl, Industry Exper	t		hl, Industry Expert			Chair: Shannon Dahl, Ind		MORE THAN JUST A MEETING
Translating Therap	ies for Hard-to-Treat Ind		30 CAR ProTcell, Toward New G	-		inhancing (Cell Therapy Persistence	& Reducing Exhaustion	SPEAKERS
11.00 A Landscape Over	view of CAR & TCR Thera		Leveraging the potential of T- cell therapy	cell progenitors for allogen	: 4.	.00 Enforci	ng Memory-Associated ersistence & Potency	Programs to Enhance	
landscape	ds in the CAR and TCR the	, apy	Achieving in vivo differentiation cellular immunotherapy produce Developing a new generation	icts	•	Overexpres	ssing memory-associated a memory-like phenotyp	transcription factors be, thus increasing	AGENDA AT A GLANCE
hard-to-treat solid tun	how will therapies become nors? to accelerate the clinical	Succession	cells livier Negre, Chief Scientific O	J	•	Enhancing and in vivo	CAR-T cell anti-tumor ac	, .	WORKSHOP DAY
of your own cell therap Rachel East , Lead Resea			Implementing a Strategy to Perfor	Measure & Optimize Clini mance	cal E	therapeuti van Weber,	c T-cell states for cancer i Assistant Professor of Peo	mmunotherapies	FOCUS DAY
	ring on Automated Biored	actor to of	00 In Process Measurements f CAR-T Cells for Advanced Pr	of Critical Quality Attribu	ites d	f Philadelp .30 The Pov	hia wer of Immune Receptor ontier of Cancer Cell The	Sequencing to Inform	DISCUSSING DIVERSITY AT CAR-TCR
	Islation of Cell & Gene Th	-	anufacturing		D	isease Bure	den Assessment	., .	
Next generation manu	unities in cell therapy prod facturing strategies rocess to the Cocoon® Plat		The importance of identifying attributes of CAR-T cells for de CAR-T		ıs	capabilitie T-cell deve	state-of-the-art T-cell ar s can be leveraged in mu elopment - from product c sistence tracking to long-	tiple phases of CAR haracterization and	CONFERENCE DAY 1
Tamara Laskowski, Seni Lonza	or Director, Clinical Develo	•	The importance of in-process process development and ma The importance immune cell r effector function (potency) an safe and efficacious CAR-T pro	nufacturing workflows netabolic measurements, d cell phenotype for design	ed •	monitoring TCR seque product ch infused T c The FDA-cl		le enables quantitative ive in vivo tracking of es types and time points d clonoSEQ MRD assay	CONFERENCE DAY 2
12.00 Panel Discussion: Hard-to-Treat Indicatio	Developing Novel Thera ons	pies for Y	ama Abassi, Associate Vice Pre usiness Development, Agilent		g &	cellular the	erapies with industry lead ardization	with NGS-MRD, Adaptive	CONFERENCE DAY 3
	e made in the past few yea allenges when translating ⁻ nors?	therapies for 2.	30 Implementing a Customiz easure & Optimize Clinical Po)	can provid	e unmatched response ch rden assessment, and hel	aracterization, sensitive	PARTNERS
 How can we address the 			roducts	2	M	latt Knight iotechnolo	, Senior Manager, Biopha	rma, Adaptive	PARTNERSHIP
Arthur Stril, Chief Busine Chantal Kuhn, Director, I	ess Officer, Cellectis Head of T-Cell Programs, C		Implementing a relevant suite development of immunogenic products	,	ack Jo Bi	ay Patel , Se iotechnolo	enior Medical Science Lia: gies	•	OPPORTUNITITES
Therapeutics			Developing standardized qua		5. W	.00 Improv ith Switch	ing TCR-T Therapeutics Receptors	Persistence & Efficacy	PRICING & DISCOUNTS
	ssor & Chief of Hematolog California; Angeles Thera	peutics .	innovative exploratory metho Implementing use of pharmac product activity and establish Ioria Jih, Principal Scientist, Ce	odynamic markers to meas mechanisms of actions	sure •	Developing TCR-T ther Merging th PD1-41BB s Resulting in	g MDG1015, a 3rd generat apy ne TCR with diverse enhar witch receptor n increased T-cell persiste	ncement tools like our ence, reduced T-cell	
12.30 Lunch Break		3.	00 Afternoon Break & Tech S	lam	•		n and elevated tumor killin endel, Chief Scientific Off	•	
			ear the latest innovations that lerapy development!	promise to revolutionize ce	ll 5.	.30 Drink's	Reception ers for some informal netv		$\overline{\mathbf{i}}$
24 www.car-tcr-s	ummit.com Tel: +16	17 455 4188 Ema i	l: info@hansonwade.co	m in Cell Immunothe	-	, 1		5,	REGISTER

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

	/* 5		
	Y-STAGE CLINICAL CLINICAL OPERATIONS MANUFACTURING CI RATEGY TRACK TRACK TRACK	MC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION & TRACK LOGISTICS TRACK MARKET ACCESS TRACK	WELCOME
MORNING SESSIONS	POST-LUNCH SESSIONS	AFTERNOON SESSIONS	
Chair: Leopold Sellner, Senior Medical Director, Cell The Development, Takeda Oncology	rapy Chair: Leopold Sellner, Senior Medical Director, Cell Therapy Development, Takeda Oncology	Chair: Leopold Sellner, Senior Medical Director, Cell Therapy Development, Takeda Oncology	MORE THAN JUST A MEETING
Preparing for IND Submission to the FDA	Sharing Early-Stage Clinical Results & Strategy	4.00 Clinical Insights from a Novel BCMA-directed CAR-T Manufactured Using the T-Charge Platform	SPEAKERS
11.00 Bringing Solid Tumor & Hematologic Pipeline Thro IND into Early Clinical Development	Leads to Excellent Clinical Efficacy & Safety	 Reducing manufacturing time to <2 days using T-Charge™, an innovative platform 	AGENDA AT A GLANCE
 Sharing aspects of our IND preparations and package fo allogeneic cell therapy pipeline Discussing the strategy for early clinical development 	cell therapy with next day manufacturing capabilitiesOvercoming safety concerns such as CRS and ICANS	 Resulting in robust expansion and prolonged CAR-T cell persistence Presenting updated clinical and biomarker data from 	WORKSHOP DAY
Assessing choices and tradeoffs when submitting INDs Kristin Yarema, President, Cell Therapy, Poseida Therape	Sharing clinical results from 29 4L+ multiple myeloma (MM) patients, as well as 16 newly diagnosed MM patients Samuel Zhang, Chief Business Officer, Gracell Biotechnologies	the ongoing Phase 1 study of PHE885, a T-Charge™ manufactured BCMA-directed CAR-T cell therapy, in patients (pts) with r/r multiple myeloma (RRMM)	FOCUS DAY
11.30 Specificity Testing of Antibodies, Bispecifics & CAI Therapeutics for IND Using the Membrane Proteome Ass	R-T	Serena De Vita, Senior Clinical Program Leader, Translational Clinical Oncology, Novartis Institute for BioMedical Research	DISCUSSING DIVERSITY AT
 Assessing off-target antibody reactivity is a regulatory requirement for clinical development; however, convention screening methods are often ineffective in screening new therapeutic modalities including cell therapies Presenting the Membrane Proteome Array (MPA), a 6,000-protein cell-array for specificity screening and including studies describing its successful use for regulatory field to the MPA has been proposed for qualification as new Drue Development Tool, and we will provide an update on its status with the FDA Rachel Fong, Director, Sales & Alliances, Integral Molecular 	Regulatory & Technical Success • Understanding how AI and modeling can help design trial protocols that predict and mitigate key risks or patient safety events clude • Understanding and selecting patient subpopulations to positively respond to your therapy • Using commonly collected lab markers from trial participants and benchmarking against past trial data to predict and mitigate severe adverse events ar • Understanding how to generate compelling evidence for	 4.30 Panel Discussion: Strategies for Successful Clinical Development of Cell Therapies Explore the latest strategies for navigating the complexities of clinical trial execution Identify clinical development best practices Learn insights into the cutting-edge advancements that are driving the future of cell therapies Moderator: Teresa Pokladowski, Regional Vice President, Clinical Business Solutions, Precision for Medicine Andy Kinley, Vice President, Innovation & Clinical Science Precision for Medicine 	CAR-TCR CONFERENCE DAY1 CONFERENCE DAY2 CONFERENCE DAY3
 Planning for IND Submission At what point should the regulatory strategy for IND be in pl What are the common pitfalls with respect to initial IND 	Tanmay Jain, Senior Director, Trial Design Solutions, Medidata	Dawn Buchanan, Vice President, Clinical Operations, Affyimmune Therapeutics Christopher Heery, Chief Medical Officer, Arcellx	PARTNERS PARTNERSHIP OPPORTUNITITES
applications? • How can you plan to avoid these issues? Lynn Bayless, Vice President, Head of Regulatory Affairs, Mustan Kristin Yarema, President, Cell Therapy, Poseida Theraper Mike Jones, Senior Manager, Custom Services, STEMCELL Technologies	 gBio Observing 100% ORR and 71% CR rate in 38 patients in phase 1 	 5.00 Sharing CD20-Directed CAR-T Clinical Data & Strategy Giving an overview of the CD20-directed CAR-T landscape Presenting data from clinical trials, sharing a cross-trial comparison Sharing overarching clinical strategy Bruce Dezube, Senior Vice President, Head of Clinical 	PRICING & DISCOUNTS
	3.00 Afternoon Break & Tech Slam Hear the latest innovations that promise to revolutionize cell therapy development!	Development, Mustang Bio 5.30 Drink's Reception	
12.30 Lunch Break		Join your peers for some informal networking, drinks & nibbles.	\ominus
5 www.cgr-tcr-summit.com Tel: +1 617 45	5 4188 Email: info@hansonwade.com in Cell Immunotherapy	x MacAR TCell Preview the Event	REGISTER





REGISTER IN ADVANCE TO SAVE \$150

DISCOVERY TRANSLATION EARLY-		: & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION &
		TRACK LOGISTICS TRACK MARKET ACCESS TRACK WELCOM
MORNING SESSIONS Chair: Ekatherina Goryachikov, Vice President, Head of Clinical Operations, Adicet Bio	POST-LUNCH SESSIONS Chair: Ekatherina Goryachikov, Vice President, Head of Clinical Operations, Adicet Bio	AFTERNOON SESSIONS Chair: Ekatherina Goryachikov, Vice President, Head of Clinical Operations, Adicet Bio
Establishing New Clinical Programs, Teams & Operation	s Managing Complex Cell Therapy Clinical Trials	Overcoming Challenges in Patient Recruitment, Retention & SPEAKER
11.00 From Mouse to Human Clinical Trial in Under 2 Years Under \$10 Million	& 1.30 Deliver High Quality Cell & Gene Therapy Clinical Trials by Selecting & Managing the Right CRO & Vendor Partners	4.00 Recruitment Strategy in a Highly Competitive Cell AGENDA AT GLANCE
 Translating autologous mouse Sirpα low macrophage ther to autologous human Sirpα low macrophage therapy Establishing operations for a new clinical program 	Managing a trial in coordination with a CRO/vendor oversight	 Developing patient/site-centric study designs Out-of-the-box thinking for site identification/selection Leveraging relationships with study investigators and site
Choosing the right CRO and CDMO Robert Towarnicki, Founder, President & Chief Executive	Danielle Quarles, Senior Director, Clinical Operations, Sana Biotechnology	staff FOCUS DA Paulius Ojeras, Executive Director, Clinical Operations, Nkarta
Officer, SIRPant Immunotherapeutics		Therapeutics DISCUSSIN DIVERSITY CAR-TCR
		CONFEREN DAY1
11.30 Group Discussion Session	2.00 Group Discussion Session	4.30 Biomarker Sample Collections in the Age of Personalized Medicine – Operational Challenges Associated with CAR-T Trials DAY 2
12.00 Panel Discussion: Building New Clinical Programs & Operations in Small Biopharma	 2.30 Setting Up a Multicentered CAR-T Clinical Trial Setting up a clinical trial with increasing complexity and tight 	 Understanding key immune monitoring questions during CAR-T cell therapies Optimizing Schedule of Activities to maintain high patient DAY 3
With limited resources, how can small biotech set up a cell therapy trial effectively?What challenges have we encountered, and what are the	timelines Building the budget Determining the number of sites you need to recruit for the 	 compliance for longitudinal biomarker studies Customizing testing logistics for samples with short stability window on a global scale
 main lessons learned? How do we find the right CRO to work with? Dawn Buchanan, Vice President, Clinical Operations, 	number of patients required Ann Murphy, Senior Director, Clinical Operations, Poseida	Vincent Leveque, Principle Scientific Manager, Genentech PARTNERSE OPPORTUNIT
Affylmmune Therapeutics Ann Murphy, Senior Director, Clinical Operations, Poseida Therapeutics Kevin Zikaras, Industry Expert Abhi Gupta, Senior Vice President, Head of Cell & Gene There Syneos Health	Ipy,	5.00 End of Track PRICING & DISCOUNT
12.30 Lunch Break	3.00 Afternoon Break & Tech Slam Hear the latest innovations that promise to revolutionize cell therapy development!	5.30 Drink's Reception Join your peers for some informal networking, drinks & nibbles.
26 www.car-tcr-summit.com Tel: +1 617 455	188 Email: info@hansonwade.com in Cell Immunotherapy	



27



REGISTER IN ADVANCE TO SAVE \$150

		EARLY-STAGE CLINIC STRATEGY TRACK		MANUFACTURING TRACK				COMMERCIALIZATION & MARKET ACCESS TRACK	
MOR	RNING SESSIONS	:	POST-LUNCH	SESSIONS	:		AFTERNOON SE	SSIONS	WELCOME
Chair: Sanjin Zvo	nić , Senior Vice President, ctice Expert, Dark Horse C		Chair: Sanjin Zvonić , Senio Development & Practice Expo	or Vice President, Business			Sanjin Zvonić, Senior Vic nent & Practice Expert, E	e President, Business	MORE THAN JUST A MEETING
Optimizing Manufa	cturing Processes & Qual	ity Control	Reducing Vein-to-Vein Time t	o Improve Speed to Patie	ent	Building &	& Optimizing Your Own I	Manufacturing Facility	SPEAKERS
	Seneration Cell Therapy Without Compromising Q		.30 Streamlining Manufacturir o-Vein Time	ng Processes to Improve V	'ein-		novation to Clinical Ma se I Cell Therapy Engine	-	AGENDA AT A GLANCE
efficacies	abilities to improve manufo es in scaling out cell therap	by production	Discussing the evolution of the for TCR-T cell therapies through development Enhancing manufacturing and	h various stages of clinical		 Bringing in unique set 	in cell therapy product of novation in Phase I clinic ting g facility design for clinico	al manufacturing, a	WORKSHOP DAY
0	ons and opportunities for f by manufacturing processe	urther •	Making continuous improveme and reduction of vein-to-vein t	ents to expedite release tes	ting	Nelly Viseux	, Senior Vice President, Pr t & Clinical Manufacturin	ocess & Analytical	FOCUS DAY
Vaishali Shukla, Vice Pr Manufacturing, Kite, A (esident, Quality, Commerc Gilead Company		Ni Mohamed , Senior Vice Preside 2.00 Key Considerations in Build			4.30 Panel D	iscussion: Keys to Succes		DISCUSSING DIVERSITY AT CAR-TCR
Manufacturing of Allog Materials • Improving patient acc • Cultivating an industr	et Approval & Driving Sus geneic CGT through Healt cess: is the industry ready t ry-driven donor ecosystem accelerate speed to marke ring	stainable hy Donor . o innovate? .	Partnerships for Cell Therapy M Reviewing a case study for stro an innovative biotech startup of therapy, sharing experience fro Exploring the current manufac challenges faced by new indus strategic partnership can help eventually overcome these hur	ategic manufacturing betw and services provider for ce om both parties turing obstacles and try entrants, how the prope them assess, prepare and	11	 innovative Gain key insoperations systems 	ndustry experts on their ap commercial cell therapy m sights into building out the infrastructure and project It various phased impleme	anufacturing facility appropriate technical workstreams and quality	CONFERENCE DAY 1 CONFERENCE DAY 2
Yuki Maves, Senior Proc	duct Manager, AllCells	•	Sharing best practice example synergistic relationship to bring		ht		John Khoury , Executive Vic gh , Chief Technical Officer,	e President, Project Farma	CONFERENCE DAY 3
While Ensuring Product	: Reducing Manufacturin t Quality innovate the manufacturir	- -	John Trzupek, Chief Operating C Andrew Sandford, President, Ele		CS	5.00 Moving) from External to Interi erapy Products		PARTNERS
Should we ship unreleHow can we optimize		rol processes?	2.30 Fully Automated High Yiel Manufacturing Process Leveraging a flexible, closed, fu	-		 Sharing the and buildir Ensuring p 	e benefits and challenge ng your own internal mar rocess consistency and p	roduct yield	PARTNERSHIP OPPORTUNITITES
Manufacturing, Bristol I Vaishali Shukla, Vice Pr Manufacturing, Kite, A Brian Mullan, Chief Tech	resident, Quality, Commerc Gilead Company	ial • •	platform Developing a one week manufer reproducible, and scalable Optimizing a process that supp with a favourable phenotype Cajesh Krishnan, Chief Technolog Therapeutics	acturing process that is ports production of CAR-T c		production		Mink Therapeutics	PRICING & DISCOUNTS
12.30 Lunch Break		3 H	5.00 Afternoon Break & Tech Si Hear the latest innovations that p herapy development!		I	5.30 Drink's Join your pee	•	working, drinks & nibbles.	$\overline{\rightarrow}$
27 www.car-tcr-	summit.com Tel: +1 (il: info@hansonwade.con	n <mark>in</mark> Cell Immunothe	erapy 🎽	@CAR_TCe	ll 🕒 Preview the I	Event hansonwade	REGISTER

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

		IC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION &
TRACK TRACK STRAT	EGY TRACK TRACK TRACK POST-LUNCH SESSIONS	TRACK LOGISTICS TRACK MARKET ACCESS TRACK WELCOME WELCOME
Chair: Damien Fink, Director, Analytical Development, Century Therapeutics	Chair: Damien Fink, Director, Analytical Development, Century Therapeutics	Chair: Damien Fink, Director, Analytical Development, Century Therapeutics MORE THAN JUST A MEETING
Optimizing Characterization to Better Predict Cellular Attributes	Developing Characterization Strategies for Ancillary Materials & Cell Product	Discussing Regulatory Guidance to Ensure CMC Regulatory Compliance
11.00 Establishing Fit-for-Purpose Cell Measurements to Better Predict Cellular Attributes	 1.30 Best-in-Class Characterization of Ancillary Materials Leveraging supplier data for introduction of new materials 	4.00 Regulatory CMC Landscape for CAR-T Products AGENDA AT A • Overviewing CAR-T regulatory CMC guidance GLANCE
 Designing fit-for-purpose cell assays that are correlative wit cell outcome Utilizing concepts from existing standards to design 	 Developing phase appropriate characterization strategies for raw materials Applying ancillary material best practices based on existing 	 Discussing the significance of re-organization at CBER and the new super office (OTP) Exploring CMC opportunities and challenges in 2023 and
experiments and optimize measurement techniques • Developing a matrix-based approach toward cell viability	 Apprying difficulty indefinition best practices based on existing guidance documents Lili Belcastro, Senior Principal Scientist, Bristol Myers Squibb 	Exploring Civic opportunities and chaininges in 2023 and beyond FOCUS DAY Michael Lehmicke, Vice President, Science & Industry Affairs,
measurements Laura Pierce, Biomedical Engineer, National Institute of Standards & Technology	 2.00 Overcoming Challenges to Lock your CAR-T Cell Therapy Process & Speed Your Path to Clinic Developing closed, controlled and automated processes for 	Alliance for Regenerative Medicine DISCUSSING DIVERSITY AT CAR-TCR
 11.30 An Academic Lab Perspective on Next-Generation CART19 Products' Identity, Purity & Potency Session details to be announced 	 CAR-T therapies remains a challenge Catalent's fully closed GMP compliant autologous CAR-T cell platform uses data-driven guidance to build a seamless, robust, modular workflow for both autologous and allogeneic 	4.30 Achieving Efficient & Scalable Lentiviral Vector DAY1
Patrizia Porazzi, Senior Research, Investigator, Center for Cellular Immunotherapy, University of Pennsylvania	cell therapies, minimizing risk without compromising on quality.Learn more about Catalent's UpTempoSM CAR-T Cell Therapy	 What is the EuLV stable producer cell line development platform How to develop lentiviral vector producer cell lines using the
12.00 Panel Discussion: Exploring the Future of Cell Therap Characterization to Ensure High Quality Products	Platform TBC, Catalent	EuLV platform • What is the EuBioX - an automated monoclonal screening platform CONFERENCE DAY 3
• What are the current challenges when characterizing your therapy? How can we solve this issue?	2.30 Exploring Innovation in Analytical Development to Facilitate Cell Therapy Product Development	A real-world case study of a reliable and scalable LVV production workflow PARTNERS
 How can we provide more systematic and unbiased insights to enable deeper characterization? What new equipment and methodologies can we utilize? 	 Discussing the CMC consideration for cell therapies Discussing the analytical strategy for the characterization of starting materials and product for quality, safety, and efficacy 	Roy Li, Chief Operation Officer, Eureka Bio 5.00 Lentiviral Vector CMC Considerations for CAR-T Therapies
Edward Armstrong, Vice President, Quality, Mustang Bio Troy Lionberger, Senior Vice President, Business Development, PhenomeX Shibani Mitra-Kaushik, Head, Product Control Strategy & Analytics, Takeda	Discussing what and how innovation analytics to facilitate	 Developing best practice for using lentiviral vectors in gene transfer for gene-modified T-cell therapy manufacturing Describing lentiviral vector CMC considerations for clinical use Understanding how vector quality impacts CAR-T cell quality Seraphin Kuate, Director, Global Regulatory CMC, CAR-T Cell
Jie Wei, Director, Analytical Sciences, Tr1X Bio	3.00 Afternoon Break & Tech Slam	Therapy, Bristol Myers Squibb 5.30 Drink's Reception
12.30 Lunch Break	Hear the latest innovations that promise to revolutionize cell therapy development!	Join your peers for some informal networking, drinks & nibbles.



REGISTER

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

DISCOVERY TRANSLATION EARLY-STAC TRACK TRACK STRATEG		MC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION & TRACK LOGISTICS TRACK MARKET ACCESS TRACK	
MORNING SESSIONS	POST-LUNCH SESSIONS	AFTERNOON SESSIONS	WELCOME
Chair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America	Chair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America	Chair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America	ORE THAN JUST A MEETING
Transitioning from Clinical to Commercial Supply Volumes	Implementing Effective Risk Mitigation Strategies for a Robust Supply Chain	Interfacing Effectively with Internal & External Stakeholders	SPEAKERS
 11.00 Setting Up & Managing an Optimized Supply Chain to Support Phase Appropriate Growth Demonstrating good operations management and organizational set up for optimized and cost effective end- to-end logistics 	 1.30 Patient Considerations for the Management of Cycle Times for Autologous Cell Therapies Exploring parallels and touch-points between the patient and cell journey 	Clinical Trial Onboarding Managing the interface with CDMOs and clinical sites to	AGENDA AT A GLANCE VORKSHOP DAY
 Introducing cell therapy supply chain models and phase appropriate setup Addressing challenges in setup and operation of manufacturing sites and logistics processes for clinical trials and key takeaways from global commercial launch experiences 	 Working with your partners to hit cycle times David Kim, Head of Supply Chain, Arcellx 	 Providing a start-up company perspective on how to supply planning Developing systems to manage early clinical logistics Thomas Tredennick, Associate Director, Clinical Supply Chain, Arsenal Bio 	FOCUS DAY DISCUSSING
Shah Ahmad, Senior Director, External Manufacturing & Supply Chain, Immunomic Therapeutics	2.00 Developing a Robust Supply Chain Through Contingency Planning		DIVERSITY AT CAR-TCR
 11.30 Capacity for Autologous Therapies: Neutral Third-Party Platforms to Support Growth Limiting variability in starting materials and ensuring a high-quality product through an ISO 9001:2015 certified Quality Management System Growing capabilities and geographic footprint: setting up supply chain to support phase appropriate growth thereby saving time and money Ensuring an integrated work flow: key considerations when building a partnership Detailing a centralized, single source, account management 	 Understanding the importance of contingency planning in a dynamic world Positioning yourself for success through pre-clearance and supplier balancing Thinking ahead; planning for growth and scalability Matthew Plaud, Chief Operations Officer, IntegriCell, Cryoport Systems 2.30 Presentation TBC Session details to be announced 	 Discussing ultra cold supply chain challenges for temperature sensitive critical materials Improving visibility of your critical materials in transit to ensure compliance Mitigating cost and timeline risks through customized solutions for comparing analyzing intra labeling. 	CONFERENCE DAY1 CONFERENCE DAY2 CONFERENCE DAY3
team to ensure services meet your current and evolving needs Michelle Hensey , Process Excellence, Therapeutic & Cellular Solutions (TCS), American Red Cross Blood Services			PARTNERSHIP
 12.00 Panel Discussion: Overcoming Logistical Challenges with a Solution to Commercialization How can we prepare to scale logistical workflows? How do we achieve standardization? What future challenges can we expect as the field moves further towards commercialization? Chris Baldwin, Senior Director, Cell & Gene Therapy Supply Chain, GSK 		 How can we improve internal and external communications? What is the best way to establish an effective supply chain infrastructure? 	PPORTUNITITES PRICING & DISCOUNTS
 Shah Ahmad, Senior Director, External Manufacturing & Supply Chain, Immunomic Therapeutics 12.30 Lunch Break 	3.00 Afternoon Break & Tech Slam Hear the latest innovations that promise to revolutionize cell therapy development!	5.30 Drink's Reception Join your peers for some informal networking, drinks & nibbles.	$\overline{\rightarrow}$

hansonwade

REGISTER

NOW



REGISTER IN ADVANCE TO SAVE \$150

		EARLY-STAGE CLINI STRATEGY TRACI						COMMERCIALIZATION & MARKET ACCESS TRACK	
MOR	NING SESSIONS	:	POST-LUNC	H SESSIONS	•		AFTERNOON SE	SSIONS	WELCOME
Chair: Jodie V	Vehling , Vice President, Ma ss & Trade, Mesoblast	rket	Chair: Jodie Wehling,	Vice President, Market de, Mesoblast		с	h air: Jodie Wehling , Vice Access & Trade, M	President, Market	MORE THAN JUST A MEETING
Gaining Insigh	nt into the Payers Perspec	tive	Exploring Strategies for Prici	ing & Reimbursement Succe	ess	Developin	ng a Strategy to Reach M States	arkets Beyond the United	SPEAKERS
11.00 Future Directions Gene Therapies	s on Drug Pricing Models fo		1.30 Exploring Provider Driver Challenges	n Reimbursement & Access			loping Market Access St Therapies	ategy Beyond the US for	AGENDA AT A GLANCE
reimbursement for cel	the horizon for access, prici II therapies Cell & Gene Therapy Access I		 Moving from inpatient to outp Federal 340B reduced drug p Increasing provider capacity i 	rices for hospitals	US	of CAR-T	cell therapies	lenges in value assessment ve timely and broad access	WORKSHOP DAY
	ire of outcomes-based agre		 Designing innovative paymen incentives as well as the paye 	t models must consider provi	ider		patients in hard-to-reach		FOCUS DAY
 Measuring the impact and gene therapies 	nanufacturers together t and success of CMMI's effo	orts in cell	Mark Trusheim, Strategic Dire Center	ctor, NEWDIGS, Tufts Medico	al	Jie Zhang, Novartis	, Vice President, Head of C	ell & Gene Value & Access,	DISCUSSING DIVERSITY AT CAR-TCR
	ty Director, Seamless Care N licare & Medicaid Services								CONFERENCE DAY1
									CONFERENCE
11.30 Panel Discussion: Therapy Access Model	Discussing the New Cell &		2.30 Roundtable Session: Impl Strategies to Make Cell Thera				ing a Successful Market / alization Strategy for All		DAY 2
to achieve better care			What is the right pricing stratWhat are the potential solution		ies?		ing a US and global marke		CONFERENCE DAY 3
 How should the new p What challenges still I Moderator: 	bayment models be implem lie ahead?	ented?				Discussin	n to maximize patient acc ng readiness strategies for ing a unique "Go To Marke	commercialization	PARTNERS
	Care Models Group, CMMI C	Centers for				strategy	based on the precise need of the potential market		PARTNERSHIP
Speakers:						Jodie Weh Mesoblast	ling , Vice President, Marke	et Access & Trade,	OPPORTUNITITES
Katherine Szarama, Di	rector, Drug Pricing, Arnold	Ventures				mesobiusu			PRICING &
Brett Logan, Independ						5.00 End o	f Tunck		DISCOUNTS
Brent Rice, Senior Vice F Head US, Autolus	President, Chief Commercia		3.00 Afternoon Break & Tech S		6 6 6	5.00 End 0	DT Irack		
Aurelia Chaudhary, Cel Seamless Care Models G	II & Gene Therapy Access M Group, CMMI Centers for M o	lodel Lead,	Hear the latest innovations that therapy development!	promise to revolutionize cell					
Medicaid Services					- - - - -	5.30 Drink	's Reception		
12.30 Lunch Break					• • • •	Join your p	peers for some informal net	working, drinks & nibbles.	$\overline{\mathbf{i}}$
				m 🗔 Call Immunathar		CAD TO			DECISTED

30 www.car-tcr-summit.com Tel: +1 61/ 455 4188 Email: info@hansonwade.com in Cell Immunotherapy y@CAR_ICell Dreview the Event



DAY 2 OVERVIEW

Thursday, August 31

Use the buttons to below to navigate straight to your favourite track!

A CONTRACTOR	DISCOVERY	\bigcirc
TA	TRANSLATION	\bigcirc
the contract	EARLY-STAGE CLINICAL STRATEGY	$\overline{\bigcirc}$
	CLINICAL OPERATIONS	$\overline{\bigcirc}$
	MANUFACTURING	$\overline{\mathbf{i}}$
	CMC & ANALYTICS	$\overline{}$
	SUPPLY CHAIN & LOGISTICS	
	COMMERCIALIZATION & MARKET ACCESS	
EG		

MORNING PLENARY SESSIONS

→ Demonstrating success in solid tumors

DISCOVERY TRACK

- Transforming solid tumor treatment with innovative platform technology
- → Leveraging novel approaches to targeting solid tumors
- Utilizing high throughput methods to revolutionize drug discovery and development

BEARLY-STAGE CLINICAL STRATEGY TRACK

- Developing combination strategies to enhance cell efficacy
- Enhancing clinical efficacy with immunosuppression strategies
- → Exploring different administration/dosing regimens to optimize clinical efficacy

MANUFACTURING TRACK

- \bigcirc Optimizing manufacturing with innovative technology and equipment
- → Leveraging partnerships to accelerate development
- Recruiting, training, and retaining skilled workers in manufacturing

SUPPLY CHAIN & LOGISTICS TRACK

- ⊖ Implementing digital systems to transform end-to-end development
- \bigcirc Addressing chain of identity and custody concerns to improve traceability
- ⊖ Outlining best practices from world-class research centers

AFTERNOON POSTER SESSION

Submit your abstract here before Friday, July 28 to get involved

High-quality abstracts will be judged by our esteemed CAR-TCR Advisory Board, who will decide the CAR-TCR Poster Award winner

TRANSLATION TRACK

- Using novel gene engineering technologies to improve cell
 therapy function
- \bigcirc Demonstrating success through use of preclinical models
- Spearheading therapeutic development by leveraging the innate immune system

CLINICAL OPERATIONS TRACK

- ⊖ Preparing for large-scale national and international clinical trials
- \bigcirc Expanding access to cell therapy clinical trials
- ⊖ Ensuring clinical trial best practice and compliance

CMC & ANALYTICS TRACK

- ⊖ Exploring CMC strategy to ensure product safety and efficacy
- Overcoming potency assay development challenges to elucidate biological activity
- → Assessing safety of genetically modified cell therapies

COMMERCIALIZATION & MARKET ACCESS TRACK

- Developing an effective infrastructure to support commercialization
- ⊖ Highlighting key considerations for a successful commercial launch
- ⊖ Incorporating the patient voice into market access strategies

REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES


> PRICING & DISCOUNTS





August 29 - September 1, 2023 CAR-TCR Boston, MA





hansonwade



REGISTER IN ADVANCE TO SAVE \$150

MORNING SESSIONS	POST-LUNCH SESSIONS	AFTERNOON SESSIONS	WELCOME
Chair: John Maher, Chief Scientific Officer, Leucid Bio	Chair: John Maher, Chief Scientific Officer, Leucid Bio	Chair: John Maher, Chief Scientific Officer, Leucid Bio	MORE THAN JUS A MEETING
Transforming Solid Tumor Treatment with Innovative Platform Technology	Leveraging Novel Approaches to Targeting Solid Tumors	Utilizing High Throughput Methods to Revolutionize Drug Discovery & Development	SPEAKERS
1.30 Nanrilkefusp Alpha, IL-15 Superagonist in Combination with CAR-T & BOXR-T Cells Enhances Anti-Tumor Efficacy Combining IL-15 agonism with CAR-T enhances T-cell response in preclinical models Enhancing treatment with tunable dosing scheme Adding benefit in addition to T-cell coded enhancements any Jensen-Smith, Vice President, Discovery Research, SOTIO Notech	 2.00 Cytotoxic Immune Cells Engineered with a Chimeric ILT-Receptor Chimeric ILT-Receptor (CIR): a novel approach in cell therapy using natural receptor binding to tackle leukemia and solid tumors Addressing tumor immunosuppressive effect with engineered CIR-NK/CIR-T cells Building a cost-effective off-the-shelf technology to improve accessibility Raphaël Ognar, Co-Founder & Chief Executive Officer, NKILT Therapeutics 	 4.30 Automation at Arsenal: Enabling Massively Parallel Genetic Engineering for Drug Product Development Developing and scaling Arsenal's automation to enable large scale research experiment for drug development and produce high quality data at an unprecedented scale Leveraging Arsenal's automation capability to explore new compositions in the CAR-T and TCR space Sophie Xu, Associate Director, Automation & High Throughput Assay Development, Arsenal Bio 5.00 Automated Solutions for Streamlining CAR-TCR Discovery Workflows 	AGENDA AT A GLANCE WORKSHOP DA FOCUS DAY DISCUSSING DIVERSITY AT CAR-TCR
2.00 Cell Avidity Drives the Functional Responses of cell Therapies, Providing Superior Correlates to In Vivo erformance Developing a quick in vitro assay with robust correlation in vivo (R^2: 0.9) Leveraging avidity assays to positively rank and negatively cull candidates in the same assay Reducing the time and expense to murine studies while increasing confidence in lead selection VIII Singleterry, Director, Immuno-oncology & Commercial,	 2.30 Therapeutics Efficacy & Mechanism of IL-7/CCL19- Producing CAR-T Cells in Solid Cancers Engineering PRIME CAR-T cells to produce IL-7 and CCL19 for the treatment of solid cancers containing CAR target- negative population Inducing epitope-spreading to endogenous tumor neoantigens following the treatment with PRIME CAR-T cells Promoting DCs with a potential of cross presentation by the treatment with PRMIE CAR-T cells Koji Tamada, President & Chief Executive Officer, Noile- Immune Biotech 	 Automating synthetic biology and multiomic workflows to streamline CAR engineering Enabling rapid expression and screening of TCRs through automated mRNA synthesis Overcoming synthesis bottlenecks for novel mRNA modalities with push-button solutions Applying the next-generation molecular biology workstation to optimize workflows throughout CAR-TCR discovery Jyotsna Venugopal, Director, Product Marketing, Telesis Bio 	CONFERENCE DAY1 CONFERENCE DAY 2 CONFERENCE DAY 3
2.30 Panel Discussion: Transforming a Novel Idea into a Successful Biotech Company How do you start up your own company beginning with an innovative idea? When starting a company, should you be technology focused or problem focused? How have you gained investment? UJ Kang, Chief Executive Officer, Appia Bio Gregory Fiore, Board Member, Eterna Therapeutics	 3.00 Roundtable Discussion: Discussing Current & Emerging Strategies to Target Solid Tumors Why has there not been much success targeting solid tumors to date? What novel engineering approaches can we utilize? How do we circumnavigate the solid tumor microenvironment? Henri Bayle, Co-Founder & Chief Technology Officer, NKILT Therapeutics Raphaël Ognar, Co-Founder & Chief Executive Officer, NKILT Therapeutics 	 5.30 High-Throughput Discovery of Novel Regulators of T-Cell Function to Build Better Immunotherapies Developing a scalable gain-of-function discovery platform in human T-cells Applying discovered modulators across different contexts: CARs and TCRs, T-cell subsets, tumor types Leveraging synthetic biology to design improved versions of natural human genes Mat Legut, Co-Founder & Chief Executive Officer, OverT Bio 	PARTNERS PARTNERSHIP OPPORTUNITITE PRICING & DISCOUNTS
.00 Lunch Break	3.30 Afternoon Break & Poster Session	6.00 End of Conference Day 2	$\overline{\mathbf{i}}$

TRANSLATION TRACK

	August 29 – September 1, 2023 Boston, MA	REGISTER IN ADVANCE TO SAVE \$150
CTURING ACK	CMC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION & TRACK LOGISTICS TRACK	
NS	AFTERNOON SESSIONS	WELCOME
Expert	MORE THAN JUST A MEETING	
reclinical Models	Spearheading Therapeutic Development by Leveraging the Innate Immune System	SPEAKERS
fic Cytotoxic	4.30 ViveNKTM: Genetically Modified Stem Cell Derived Natural Killer Cells, a New Hope for Cancer Immunotherapy	AGENDA AT A GLANCE
in preclinical	 Off-the-shelf, cryopreserved, allogeneic stem cell derived NK cells Closed feeder free system for generation of CAR-NK cells 	WORKSHOP DAY
ine, Dana-Faber	 Closed receiption of generation of CAR-NR cens Chimeric antigen receptors, CAR vector design, transduction platform development Stable and functional CAR expression against a novel target 	FOCUS DAY
Therapy in Large	as well as against CD19 and Her2 as PoC Adil Duru, Senior Research Manager, Glycostem	DISCUSSING DIVERSITY AT
ty but has weak to phoma (LBCL) tell sequencing, and	 5.00 A Universal Tool for Monitoring Multiple CAR-T Therapies in the Clinic - A Case Study for Future Clinical Development Describing development and application of multiplexed 	CAR-TCR CONFERENCE DAY 1
that prevalence t peak CAR T cell paseline lactate	 CD19-directed CAR-Ts Presenting design principals and POC data for a futuristic assay that can detect bispecific CAR-Ts, safety and reference genes in a single sample 	CONFERENCE DAY 2
tumor burden, onse compared to ral Treg (nTreg) cells	 Aiding the development of next generation CD19-directed CARs but also other novel therapeutic modalitites (e.g., hims affecting CDISCR advised CARs) 	CONFERENCE DAY 3
chool of Medicine	Shabnam Tangri, Chief Scientific Officer, Navigate BioPharma	PARTNERS
llenges of Using	5.30 Identification of NK Cell Specific CARs for iNK Targeted Knock In & Combination Treatments with CYT-303 Flex-NK™ Cell Engagers for Hepatocellular Carcinoma	PARTNERSHIP OPPORTUNITITES
nates as	 Developing a pipeline of iNK cell therapies and Flex-NK[™] cell engagers to unleash the full potential of NK cells in the tumor microenvironment Treating indications including HCC, MM and GB 	ADVANCE TO SAVE \$150 ADVANCE TO SAVE \$150 AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO SAVE \$150 AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVANCE TO AUTOR ADVENTION ADV

- Demonstrating that the combination iNK cells and Flex-
 - NK[™] cell engagers can reverse dysfunctional NK cells in the immunosuppressive tumor microenvironment

Tony Arulanandam, Senior Vice President & Head of Preclinical **R&D, Cytovia Therapeutics**

6.00 End of Conference Day 2

MORNING SESSIONS POST-LUNCH SESSIO **Chair: Shannon Dahl, Industry Chair: Shannon Dahl, Industry Expert** Using Novel Gene Engineering Technologies to Improve Cell **Demonstrating Success Through Use of P Therapy Function** 2.00 Developing & Translating Multi-Speci 11.30 Novel Non-Viral Gene Writing for Immune Cell Therapy CD4+ T-Cell (CD4 CTL) Therapy for Cancers · Leveraging circular single stranded DNA for superior non-viral Understanding CD4 CTL biology targeted genome integration Developing multi-specific CD4 CTL therapy • Engineering clinically meaningful cells with extra-large animal models transgene integration Translating CD4 CTL therapy to humans Developing functional CAR-T cells with cssDNA based non-Baochun Zhang, Assistant Professor of Medici viral gene writing platform Cancer Institute, Harvard Medical School Howard Wu, Co-Founder & Chief Scientific Officer, Full Circles Therapeutics 2.30 Determinants of Resistance to CAR-T Cell 12.00 Unlocking Allogeneic & Sold Tumor T Cell Therapies **Cell Lymphoma** with Multiplexed Genome Editing · CAR T cell expansion in blood is linked to toxicit Building durable allogeneic therapies resistant to T and NK. no association with response in large B cell lymp cell rejection with an HLA pruning approach · Using mass cytometry, flow cytometry, single-c • Ensuring scalable genome editing with lipid nanoparticles to functional studies, we identified and validated address off-the-shelf manufacturing of CAR+T regulatory (CAR Treg) cells in blood at Enhancing efficacy in solid tumors by bypassing immune expansion is linked to progression suppressive mechanisms A model combining CAR Treg prevalence with b dehydrogenase (LDH) levels, as a surrogate for Birgit Schultes, Senior Vice President, Head of Cell Therapy, was superior for predicting durable clinical resp **Intellia Therapeutics** models relying on each feature alone 12.30 Panel Discussion: Engineering the Next-Generation of · CAR Treg cells originate from pre-existing natu **Cell-Based Therapeutics** Zinaida Good. Instructor. Stanford University So • What are the best engineering modalities and approaches to 3.00 Roundtable Discussion: Emerging Cha create 'better' cells for clinical use? **Preclinical Models** How can we increase persistence and cell fitness? · What is the best way to protect cells from the tumor How do we choose preclinical animal mode microenvironment? outcomes in human trials? What are the limitations of non-human prin Sven Kili, Principal, Sven Kili Consulting translational models in immuno-oncology?

Howard Wu. Co-Founder & Chief Scientific Officer. Full Circles **Therapeutics**

Birgit Schultes, Senior Vice President, Head of Cell Therapy, **Intellia Therapeutics**

1.00 Lunch Break

3.30 Afternoon Break & Poster Session

How can we overcome these challenges?

www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com in Cell Immunotherapy 💓 @CAR_TCell 🕑 Preview the Event

hansonwade



August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

DISCOVERY TRANSLATION EARLY-STAGE TRACK TRACK STRATEGY		CMC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION & TRACK LOGISTICS TRACK	
MORNING SESSIONS	POST-LUNCH SESSIONS	AFTERNOON SESSIONS	WELCOME
Chair: Sonal Gupta, Senior Vice President, Head of Clinical Development, Affyimmune Therapeutics	Chair: Sonal Gupta, Senior Vice President, Head of Clinical Development, Affyimmune Therapeutics	Chair: Sonal Gunta, Senior Vice President, Head of Clinical	RE THAN JU MEETING
Developing Combination Strategies to Enhance Cell Efficacy	Enhancing Clinical Efficacy with Immunosuppression Strategies	Exploring Different Administration/Dosing Regimens to S Optimize Clinical Efficacy	SPEAKERS
 11.30 Addressing T-Cell Therapy into Earlier Treatment Settings Addressing the unmet medical need Moving towards regulatory approval Progression of therapy – combining immune checkpoint inhibitors and T-cell therapy into earlier lines of treatments Friedrich Graf Finckenstein, Chief Medical Officer, Iovance Biotherapeutics 	 2.00 Allogeneic CAR-T Cell Therapy for Acute Leukemias: Where are we Now? Reviewing progress in both acute lymphoid and acute myeloid leukemias Highlighting the role of alemtuzumab in the lymphodepletic regimen Discussing next steps Mark Frattini, Chief Medical Officer, Cellectis 	 4.30 Optimizing Non-Engineering Clinical Approaches to Improve Outcomes in Cell Therapies Discussing ways to leverage lymphodepletion therapies to maximize efficacy in cell therapy Leveraging dose optimization strategies to overcome response challenges to cell therapies Discussing emerging information on multi-dosing and combination therapy Ramon Tiu, Vice President & Head of Oncology Cell Therapy Diversion Takeda 	GENDA AT A GLANCE RKSHOP DA OCUS DAY ISCUSSING VERSITY A CAR-TCR
 12.00 Large-Scale Isolation of T Cells & Other Populations for Research Startup costs and easy of use with products for the isolation of T cells and other cell populations Processing apheresis products with negative selection without ficoll gradients Tim Waters, Director, Advanced Cell Processing, Bloodworks Northwest 12.30 Panel Discussion: Discussing Combination Therapy as an Opportunity for Improved Efficacy 	 2.30 Strategies for Navigating Early-Phase Trials to Develop Successful CGT Products Highlighting aspects of Candel's clinical platforms Exploring the importance of having a clear CMC strategy in the development of cell and gene therapies (CGT) Addressing key CMC issues in CGT Outlining best practices to achieve regulatory and pre-laun success Seshu Tyagarajan, Chief Technical & Development Officer, Candel Therapeutics 	 cherapies to market Optimizing cell therapy manufacturing through standardizing processes Accelerating the learning curve and overcoming roadblocks from research to GMP CDMOs vs CMOs and reshaping the common goal Anastasiya Smith, Senior Director, R&D, Marker Therapeutics 5.30 Developing a CAR-T for Ovarian Cancer & Other Solid 	DNFERENCE DAY 1 DNFERENCE DAY 2 DNFERENCE DAY 3 PARTNERS
 How can combination therapy enhance its success in treating cancer? What combinations seem the most promising? What challenges must be considered when pairing therapies? Tony Arulanandam, Senior Vice President, Head of Preclinical R&D, Cytovia Therapeutics Friedrich Graf Finckenstein, Chief Medical Officer, Iovance Biotherapeutics Leopold Sellner, Senior Medical Director, Cell Therapy Development, Takeda Oncology 	 3.00 Roundtable Discussion: Impacting CAR-T Efficacy with Pre-Conditioning Regimens What is the optimal approach to lymphodepletion for liquid and solid tumors? Should we intensity or not intensify preconditioning regimen and why? What is the best lymphodepletion approach to balance between safety and efficacy? Pamela Garzone, Chief Development Officer, Anixa Biosciences 	 Developing CAR-T in solid tumors Exploring routes of administration beyond IV Discussing the role of lymphodepletion for CAR-T in solid tumors Sharing translational and early clinical data 	RTNERSHI ORTUNITIT PRICING & ISCOUNTS
1.00 Lunch Break	3.30 Afternoon Break & Poster Session	6.00 End of Conference Day 2	



 \bigcirc REGISTER



REGISTER IN ADVANCE TO SAVE \$150

	AGE CLINICAL OPERATIONS MANUFACTURING CM	MC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION &	
TRACK TRACK STRAT	EGY TRACK TRACK TRACK	TRACK LOGISTICS TRACK MARKET ACCESS TRACK	WELCOME
Chair: Dawn Buchanan, Vice President, Clinical Operations AffyImmune Therapeutics	Chair: Dawn Buchanan, Vice President, Clinical Operations AffyImmune Therapeutics	Chair: Dawn Buchanan, Vice President, Clinical Operations AffyImmune Therapeutics	MORE THAN JUS A MEETING
Preparing for Large-Scale National & International Clinic Trials	Expanding Access to Cell Therapy Clinical Trials	Ensuring Clinical Trial Best Practice & Compliance	SPEAKERS
11.30 Building a Team & Plan to Prepare for International Clinical Trials	 2.00 Improving Patient Access to CAR-T Clinical Trials Improving patient access and experience: review of the CAR-T access team structure 	 4.30 Introduction to the FDA's Bioresearch Monitoring Program Explaining the objectives of the FDA's Bioresearch Monitoring 	AGENDA AT A GLANCE
Developing best approaches and strategies to build and internal clinical operations team from the ground up	 Exploring financial clearance strategies for CAR-T clinical trials and commercial product coverage 	 Explaining the objectives of the FDA's Bioresearch Monitoring Program Understanding the inspectional process 	WORKSHOP DAY
 Scaling the team appropriately, ensuring you have the resources to effectively support clinical trials Developing and enhancing clinical operations infrastructure to support global clinical operations 	 Overviewing clinical trial access barriers and strategies to mitigate them Claire White, Administrative Manager, Cell Therapy & 	• Examining CAR-T cell regulatory inspectional findings/trends Anne Johnson, Program Division Director, Bioresearch Monitoring, Division I, FDA	FOCUS DAY
Ekatherina Goryachikov , Vice President, Head of Clinical Operations, Adicet Bio	Transplant Section, Children's Hospital of Philadelphia 2.30 Supporting Patients & Families on their Journey to Activate the Cure		DISCUSSING DIVERSITY AT CAR-TCR
12.00 Group Discussion Session	 Giving an update on Emily Whitehead, now cured after becoming the first pediatric patient to receive CAR-T cell therapy Discussing how the Emily Whitehead Foundation helps 	 5.00 Developing SOPs, Working Instructions & Training to Guide Cell & Gene Therapy Clinical Trials Creating Standard Operating Procedures (SOPs) and working 	CONFERENCE DAY 1
 12.30 Panel Discussion: Building & Training Teams to Deliver Effective Cell Therapy Clinical Trials How should we build new teams to deliver clinical trials effectively? Given that cell therapy trials have so many unique aspects and challenges, how do we onboard new staff? How do we train and develop internal and external teams 	 connect patients and families to clinical trials and treatment programs Exploring how the Emily Whitehead Foundation will grow going into the next decade of CAR-T, and how you can help Tom Whitehead, Co-Founder, Emily Whitehead Foundation 3.00 Roundtable Discussion: Discussing Strategies to Meet Wider Patient Populations How are you encouraging diversity in clinical trials? How are you trying to improve geographical and financial accessibility? 	 instructions (WI) which cater to the details of cell and gene therapy clinical trials Developing strategies to ensure the team is well trained Ensuring research is conducted in accordance with the relevant legislation and guidelines 	CONFERENCE DAY 2 CONFERENCE DAY 3
		Rachelle Senzon, Director, Clinical Trial Operations, BioNTech	PARTNERS
effectively? Ekatherina Goryachikov, Vice President, Head of Clinical Operations, Adicet Bio		5.30 End of Track	PARTNERSHIP OPPORTUNITITES
Rachelle Senzon, Director, Clinical Trial Operations, BioNTech Heather Hughes, Industry Expert	 Discussing initiatives you have tried - what worked, what did not? Christopher Heery, Chief Medical Officer, Arcellx 		PRICING & DISCOUNTS
1.00 Lunch Break	3.30 Afternoon Break & Poster Session	6.00 End of Conference Day 2	$\overline{\mathbf{i}}$
6 www.car-tcr-summit.com Tel: +1 617 455 4	88 Email: info@hansonwade.com in Cell Immunotherapy	·	REGISTER

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING **DIVERSITY AT** CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP **OPPORTUNITITES**

> PRICING & DISCOUNTS



hansonwade

	CECCIONIC
MORNING	SESSIONS

Chair: Sanjin Zvonić, Senior Vice President, Business **Development & Practice Expert, Dark Horse Consulting**

Optimizing Manufacturing with Innovative Technology &

11.30 A Novel GD2 CAR-T Manufacturing Process for the Treatment of GD2+ Pediatric Brain Cancer: From PD to Patient Treatment

- Sharing preclinical data and development of a novel CAR-T manufacturing process
- · Process feasibility of manufacturing and development optimization of the mode for delivery of drug product
- Sharing process data, product attributes and a clinical trial update

Steven Feldman, Site Head & Scientific Director, Laboratory for Cell and Gene Medicine, Stanford GMP Facility

12.00 Design Considerations for Large Scale Stem Cell **Manufacturina Facilities**

- · Introduction to current state of stem cell manufacturing and shift to large scale
- Facility design consideration (Open vs. closed processing, risk assessments, regulatory compliance)
- Identifying operational challenges (upstream, downstream, and support areas)

Daniel Swanson, Senior Process Technologist, IPS - Integrated **Project Services**

Christian Estes, Process Group Lead, IPS - Integrated Project **Services**

12.30 Panel Discussion: Unlocking Digital Capabilities for **Accelerating Cell Therapy Manufacturing**

Develop a custom digital transformation roadmap

1.00 Lunch Break

- · Create intuitive and user-friendly workflows to enable all team members to utilize and gain insights effectively
- · Foster a culture shift within your team to establish a sustainable transformation journey

Moderator: John Lee, Senior Vice President, Cell Therapy, **Center for Breakthrough Medicines**

Jeet Sarkar, Vice President, Information Technology, Center for Breakthrough Medicines

POST-LUNCH SESSIONS

MANUFACTURING TRACK

Chair: Sanjin Zvonić, Senior Vice President, Business **Development & Practice Expert, Dark Horse Consulting**

Leveraging Partnerships to Accelerate Development

2.00 Working with a CDMO to Support Cell Therapy Manufacturing

- · Discussing critical factors for successful selection and collaboration with a CDMO
- Working together successfully to meet strict timelines Overcoming challenges

Maura Hobson, Senior Director, External Manufacturing, Sana **Biotechnology**

2.30 Ensuring a Smooth Technology Transfer to a CDMO

- · Keys to setting the stage for a successful handoff
- · Technology Transfer strategies to ensure right-first-time
- Selecting the right partner and ensuring robust communication and transparency

Catherine Tomaro-Duchesneau, Senior Director, Manufacturing Science & Technology, Roslin CT

3.00 Roundtable Discussion: Selecting & Working with a **CDMO Effectively**

- · Does the CDMO have all the technical and practical expertise you require?
- · How do you manage the tech transfer process to a vendor successfully?

Cécile Bauche, Chief Scientific Officer, Alaya.bio

Maura Hobson, Senior Director, External Manufacturing, Sana **Biotechnology**

3.30 Afternoon Break & Poster Session

AFTERNOON SESSIONS Chair: Sanjin Zvonić, Senior Vice President, Business Development & Practice Expert, Dark Horse Consulting

Recruiting, Training & Retaining Skilled Workers in Manufacturing

4.30 Improving Training & Internal Collaboration Initiatives to Address the Demand for Skilled Workers in Cell Therapy Manufacturing

- Improving the collaboration between clinical manufacturing and research and development is critical for success
- Providing clear career paths leading to better retention of key individuals and a better recruitment base

Linda Brink, Head of QA, XNK Therapeutics

5.00 De-risking Cell Therapy New Product Introduction: Harnessing the Power of Integrated Tech Transfer to GMP

- Discuss the state of the cell and gene therapy market and the complex path to transfer a preclinical process to comply with regulatory standards that can cause significant program setbacks
- · Share what is required for a standardized, scalable and robust technology transfer framework for new products that incorporates effective risk management strategies and integrated analytical services to reliably guide crossfunctional teams to GMP and beyond
- Introduce a cell therapy new product introduction approach focusing on process and analytics harnessing the power of integrated tech transfer to streamline program path to market 50% compared to traditional timelines

Matthew Hewitt, Vice President, Technical Officer, CGT & **Biologics, Charles River**

5.30 Building & Retaining a Team of Skilled Cell Therapy **Manufacturing Workers**

- Hiring a skilled and diverse workforce of over 500 people
- Developing an effective new hire orientation and training programs whilst ensuring GMP compliance
- Motivating and retaining a talented workforce

Lisa McClintock, Vice President, Site Leader, Cell Therapy Manufacturing, Bristol Myers Squibb

6.00 End of Conference Day 2







REGISTER IN ADVANCE TO SAVE \$150

	U		
DISCOVERY TRANSLATION EARLY-STAGE C TRACK TRACK STRATEGY T		MC & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION & LOGISTICS TRACK MARKET ACCESS TRACK	
MORNING SESSIONS	POST-LUNCH SESSIONS		ME
Chair: Ivone Bruno, Vice President, Preclinical Affairs & Process Development, CytoImmune Therapeutics	Chair: Ivone Bruno, Vice President, Preclinical Affairs & Process Development, CytoImmune Therapeutics	Chair: Ivone Bruno, Vice President, Preclinical Affairs & Process Development, CytoImmune Therapeutics	
Exploring CMC Strategy to Ensure Product Safety & Efficacy	Overcoming Potency Assay Development Challenges to Elucidate Biological Activity	Assessing & Ensuring Safety of Cell Based Therapies SPEAKE	RS
11.30 Designing an Effective CMC Strategy for Cell Therapy Products	2.00 Luciferase Based Potency Assays for Cell Therapies	4.30 Development of Flow Cytometry Based Safety Assays for Allogeneic CAR-T Product Release GLANC	
 Characterizing cell-based products to ensure product safety and consistency Continually evaluating critical quality attributes (CQAs) and critical process parameters (CPPs) during product 	 Understanding limitations of potency assays in current use Understanding Matador and Matador-Glo cytotoxicity assays, high-throughput luciferase-based cytotoxicity assays Understanding Topanga assay, a luciferase-based assay for measuring expression of CAR-T cells 	 Developing a Flow Cytometry based safety assay for allogeneic CAR-T therapies Identifying proper assay conditions to fit the product profile Designing product specific controls 	OP DAY
development Planning for inevitable manufacturing changes Emily Lowe, Senior Director, Head of Analytical Development, Appia Bio	Preet Chaudhary , Professor & Chief of Hematology; Founder, University of Southern California; Angeles Therapeutics	Susan Foster, Research Associate II, Beam Therapeutics DISCUSSI DIVERSITY	SING TY AT
 12.00 Addressing Cell Therapy CMC Challenges with GenScript Solutions Sharing a cell therapy process overview Discussing CMC challenges experienced in cell therapy development Overcoming these challenges with GenScript cell and gene therapy solutions Xinpo Jiang, Associate Vice President, Catalog Product Division, GenScript 12.30 Panel Discussion: Developing a Robust CMC Strategy When should we begin to develop a CMC strategy? What are the strengths and limitations of quality by design (QbD) and quality risk management (QRM) for cell therapy 	 2.30 Bioluminescent Bioassays for the Discovery & Development of Molecular & Cellular T-Cell Redirecting Cancer Therapy T-cell therapies involving genetic modification of T-cell to redirect their activity towards tumor-associated antigens, are a new paradigm in cancer treatment Potency testing of in-process material in such therapies, like lentiviral preps, is a challenge in T-cell therapies Developing a new set of bioluminescent cell-based bioassay tools for the discovery and development of T-cell based immunotherapies, to allow for rapid and simple potency qualification of CAR-T and TCR-engineered T-cells Mei Cong, Director, R&D Integrated Biology, Promega 	 5.00 Digitalization of the Environmental Monitoring for the Contamination Control of Cell & Gene Therapy Facilities Maintaining aseptic environment are crucial to prevent product contamination that can compromise the safety and efficacy of cell and gene products Monitoring and controlling environmental factors to ensure optimal conditions for cell growth and to prevent contamination Automating and digitalizing environmental monitoring will increase data integrity and traceability, streamline the process, and improve operational efficiency Félix Montero Julian, Scientific Director, bioMérieux 5.30 Overview of Testing Protocols, Stability Studies & 	ENCE 1 ENCE 2 ENCE 3
manufacturing processes?How can we develop an effective CMC regulatory compliance	3.00 Roundtable Discussion: Developing Best-in-Class	Shelf-Life Determination for Cell Products PARTNERS • Developing protocols (recovery, viability, identity, potency, OPPORTUNI	
strategy to avoid delays in clinical development? Damien Hallet, Vice President, Head of CMC, Affini-T Therapeutics Patricia Bettinger, Senior Director, Process Development, AGC Biologics Emily Lowe, Senior Director, Head of Analytical Development, Appia Bio Joy Zhou, Vice President, CMC Head, MiNK Therapeutics	 Potency Assays for Cell Therapy Products When should potency assay development begin? What should be considered during potency assay design and validation plan? How should reference materials and controls be used? Ann Durbin, Senior Director, Assay Development & Quality Control, Abeona Therapeutics 	 post-thaw recovery, homogeneity) to determine the shelf-life of cell and gene therapy products and ensure product safety throughout cryopreservation, storage, transportation and clinic Optimizing testing approaches for Inline stability, freezing & thawing profiles Yishara Chandler, Head of Manufacturing, Cytolmmune Therapeutics 	
1.00 Lunch Break	3.30 Afternoon Break & Poster Session	6.00 End of Conference Day 2	
38 www.car-tcr-summit.com Tel: +1 617 455 4188	mail: info@hansonwade.com in Cell Immunotherapy		TER



REGISTER IN ADVANCE TO SAVE \$150

	,		
DISCOVERY TRANSLATION EARLY-STAGE TRACK TRACK STRATEGY 1	RACK TRACK TRACK	C & ANALYTICS SUPPLY CHAIN & COMMERCIALIZATION & LOGISTICS TRACK	WELCOME
MORNING SESSIONS	POST-LUNCH SESSIONS	AFTERNOON SESSIONS	
hair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America	Chair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America	Chair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America	MORE THAN JUS A MEETING
Implementing Digital Systems to Transform End-to-End Development	Addressing Chain of Identity & Custody Concerns to Improve Traceability	Outlining Best Practices from Large Scale Facilities	SPEAKERS
.30 Connecting People & Processes with Technology & riving Digital Transformation Implementing a digital platform that allows full traceability end-to-end Improving control and tracking of raw material source, supply and quality Monitoring the manufacturing environment, tracking the performance of production equipment and conducting real- time analysis of cell culture samples to ensure product quality and consistency Rephen Chen , Chief Technical Officer, Tevogen Bio	 2.00 Improving Traceability Throughout the End-to-End Cell Therapy Supply Chain Employing cell orchestration platforms to guarantee traceability Limiting chain of identity errors through use of digital platforms Discussing what personal information manufacturers should handle Edward Armstrong, Vice President, Quality, Mustang Bio 	 4.30 Strategies for Overcoming the Challenges Associated with the Supply Chain & Logistics for Cellular Products Building an infrastructure to adapt to the constant evolution of therapeutic products Planning and executing the steps needed to have a reliable process Communicating the implementation of a new process; the consequences of a drift within a process and how to prevent it from happening Albert Ribickas, Assistant Director, Cell Therapy Facility Operations, Moffit Cancer Center 5.00 Critical Considerations Leveraging Success in 	AGENDA AT A GLANCE WORKSHOP DA FOCUS DAY DISCUSSING DIVERSITY AT CAR-TCR
 2.00 The Iterative Approach to a Digital Cell & Gene herapy Process: An Overview & Best Practice Identifying challenges in the digitization of CGT manufacturing Providing digital enablement of traceability in patient-specific processes Implementing electronic batch records for CGT with a best practice approach Summarizing digital data management for CGT processes udith Koliwer, Principal Consultant, Cell & Gene Therapy, örber Pharma Software 2.30 Panel Discussion: Demonstrating the Value of Digital ransformation What are the challenges that are being faced in the journey to digital transformation? Why and when should you invest in it? How do you decide the timing of those investments? What are the main lessons learned? ugie Zepka, Global Head of IT, Adaptimmune ale Hanna, Director, Cell & Gene Therapy Solutions, 	 2.30 Are Cell & Gene Therapies Dangerous Goods? An understanding of the purpose and regulatory framework of dangerous goods classifications, with a focus on UN3373 for specimens and UN3745 for genetically modified organisms The applicability of UN3373 and UN3745 classifications to cell and gene therapy shipments: our analysis yields surprising results How to reduce costs and mitigate risk: practical tips and guidance Andrea Zobel, Senior Director, Personalized Supply Chain, World Courier 3.00 Implementing the ISBT 128 Chain of Identity (Col) Identifier Utilizing the Col Identifier to link collection(s) associated with a given therapy Using the ISBT 128 Col Identifier on a non-ISBT 128 label Becoming an ISBT 128 Col Issuing Organization Karen Moniz, Technical Director, ICCBBA 	 Allogeneic HSCT/BMT to Inform Scalable Launches of Emerging Allogeneic Cell Therapies Discuss key successes and challenges in the facilitation of the most widely used life saving allogeneic cell therapy, hematopoietic stem cell transplant (HSCT/BMT) Buildout of critical, reliable infrastructure for cell harvest and therapy delivery Expanding beyond centers of excellence to improve patient access Securing a reliable and ongoing source for allogeneic donor cells from a registry o f7M+ volunteer donors Joy Aho, Director, Product Management, Be The Match 5.30 Lessons Learned from Experience & FDA Reviewers RE Supply Chain & Manufacturing Logistics at an Academic Cell Processing Facility Identifying current and future challenges in obtaining raw materials (e.g., apheresis or tumor harvests) Leveraging FDA comments on key materials and approaches to facilitate IND submissions Highlighting differences between Phase 1 Proof of Concept 	CONFERENCE DAY 1 CONFERENCE DAY 2 CONFERENCE DAY 3 PARTNERS PARTNERSHIP OPPORTUNITITE PRICING & DISCOUNTS
nerisourceBergen aveen Malhotra, Vice President, Head of Information chnology, Sana Biotechnology ephen Chen, Chief Technical Officer, Tevogen Bio 20 Lunch Break	3.30 Afternoon Break & Poster Session	and Phase 2 Requirements Sarah Nikiforow , Medical Director, Cell Manipulation Core Facility & Technical Director, Immune Effector Cell Program, Dana-Farber Cancer Institute 6.00 End of Conference Day 2	$\overline{\mathbf{i}}$
	:		
www.car-tcr-summit.com Tel: +1 617 455 4188	Email: info@hansonwade.com in Cell Immunotherapy	Image: Second content Image: Second content	REGISTE NOW

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

DISCOVERY TRACK TRANSLATION EARLY-STAG STRATEGY MORNING SESSIONS		& ANALYTICS TRACKSUPPLY CHAIN & LOGISTICS TRACKCOMMERCIALIZATION & MARKET ACCESS TRACKAFTERNOON SESSIONS	WELCO
Chair: Jodie Wehling , Vice President, Market Access & Trade, Mesoblast	Chair: Jodie Wehling , Vice President, Market Access & Trade, Mesoblast	Chair: Jodie Wehling , Vice President, Market Access & Trade, Mesoblast	MORE THAN A MEETI
Developing an Effective Infrastructure to Support Commercialization	Highlighting Key Considerations for a Successful Commercial Launch	Incorporating the Patient Voice into Market Access Strategies	SPEAKE
 11.30 Exploring Readiness Strategies for Cell Therapy Commercialization Discussing how best to structure your company internally for successful commercial production Exploring the current and future challenges faced to properly prepare for sustainable commercialization of these promising therapies Warner Biddle, Senior Vice President & Global Head of Commercial, Kite, A Gilead Company 12.00 Approaching a Successful Product Launch: Building a Commercial Organization from the Ground Up Discussing the value in organizing various cross-functional teams early to support a successful commercial cell therapy launch 	 2.00 What's Not in Your Launch Playbook? Identifying the "watch outs" for any cell therapy launch De-risking the downsides War-gaming the unexpected Steve Gavel, Senior Vice President, Cell Therapy Commercial Development, Legend Biotech 	 4.30 Supporting Patients & Families on their Journey to Activate the Cure Giving an update on Emily Whitehead, now cured after becoming the first pediatric patient to receive CAR-T cell therapy Discussing how the Emily Whitehead Foundation helps connect patients and families to clinical trials and treatment programs Exploring how the Emily Whitehead Foundation will grow going into the next decade of CAR-T, and how you can help Tom Whitehead, Co-Founder, Emily Whitehead Foundation 	AGENDAA GLANC WORKSHO FOCUS D DISCUSS DIVERSIT CAR-TC CONFERE DAY 1
Identifying the unique challenges and advantages of Iaunching a novel cell therapy as a smaller company Ensuring patients who could benefit are ultimately able to access these potentially life-saving cell therapies Dan Kirby , Chief Commercial Officer, Orca Bio	 2.30 Roundtable Discussion: Developing a Strategy for a Successful Cell Therapy Launch What challenges have you experienced in your quest to commercialization? 	5.00 Group Discussion Session	CONFERE DAY 2 CONFERE
 2.30 Panel Discussion: The Future of Cell Therapy Commercialization - Taking the Next Step How do we get cell therapies to become "mainstream" treatments? Can we tackle the issues of infrastructure by setting up a commercialization network in the US? How do we find a way together - industry, government, payers? How can we commercialize next-gen cell therapy products? Chris Bartiromo, Executive Director, Worldwide Value & Access Strategy, Cell Therapy, Lymphoma & Myeloma, Bristol Myers Equibb Lie Zhang, Vice President, Head of Cell & Gene Value & Access, lovartis 	 How did you overcome these challenges? How should we properly prepare the market, the product, and the company for future launches? Steve Gavel, Senior Vice President, Cell Therapy Commercial Development, Legend Biotech 	 5.30 Roundtable Discussion: Mapping the Patient Journey to Enhance Market Access How can we improve patient access to cell therapies? How can we better support patients and caregivers through the highly complex and often multiyear journey? How do we best identify patients who would benefit most from these types of therapies? 	DAY 3 PARTNE PARTNER OPPORTUN PRICING DISCOUI
	3.30 Afternoon Break & Poster Session	6.00 End of Conference Day 2	



DAY 3 OVERVIEW Friday, September 1

Use the buttons to below to navigate straight to your favourite track!



MORNING PLENARY SESSIONS

 \bigcirc Moving beyond $\gamma\delta$ T-cells: the rise of novel cell types

DISCOVERY TRACK

 Leveraging next generation gene delivery and transduction

EARLY-STAGE CLINICAL STRATEGY TRACK

→ Sharing clinical results and strategy for solid tumor treatments

MANUFACTURING TRACK

Iligning manufacturing capacity to patient demand

SUPPLY CHAIN & LOGISTICS TRACK

⊖ Enabling stable and secure cell storage and delivery through effective cryopreservation

AFTERNOON PLENARY SESSIONS

 \bigcirc Understanding the regulatory landscape for complex cell therapies

Patient Story Highlight: Why is Cell Therapy so Important?

Hear about Oaklynn Keller's journey receiving CAR-T cell therapy

TRANSLATION TRACK

→ Leveraging dual targeting to improve therapeutic efficacy and safety

CLINICAL OPERATIONS TRACK

ightarrow Optimizing cell therapy clinical trial design

CMC & ANALYTICS TRACK

⊖ Ensuring satisfactory product integrity with improved release testing strategies

COMMERCIALIZATION & MARKET ACCESS TRACK

⊖ Attracting investors to improve speed to clinic and commercialization

MORE THAN JUST A MEETING SPEAKERS

AGENDA AT A GLANCE

REGISTER IN ADVANCE TO

SAVE \$150

WELCOME

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS


PARTNERSHIP OPPORTUNITITES

> PRICING & DISCOUNTS



August 29 - September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150



hansonwade

August 29 - September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

MORE THAN JUST

A MEETING

SPEAKERS

AGENDA AT A

GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING

DIVERSITY AT

CAR-TCR

CONFERENCE

DAY1

CONFERENCE

DAY 2

CONFERENCE

DAY 3

PARTNERS

PARTNERSHIP

OPPORTUNITITES

DISCOUNTS

DISCOVERY TRACK

WELCOME

MORNING SESSIONS

Chair: Cécile Bauche, Chief Scientific Officer, Alaya.bio

Leveraging Next Generation Gene Delivery & Transduction

11.00 Surface Engineering of VivoVec Generates Potent In Vivo CAR-T Achieving Durable B Cell Aplasia in Non-Human **Primate Model**

- · Developing VivoVec particles for in vivo CAR-T cell generation
- Engineering VivoVec surface to enable preferential binding, activation and transduction of T cells in vivo
- Achieving durable B cell aplasia more than 70 days along with multiple CAR-T cell expansions in non-human primate

Byoung Ryu, Executive Vice President, Umoja Biopharma



11.30 Advancing Targeted In Vivo Cell Engineering

- Developing a novel targeted lipid nanoparticle (tLNP) platform with enahnced payload delivery to target cells
- Capstan's tLNPs are well tolerated with significantly decreased off-target uptake
- · Demonstrating efficient and specific reprogramming of human T cells and T cell subsets in vitro and in vivo

Haig Aghajanian, Co-Founder & Vice President, Research, **Capstan Therapeutics**

12.30 Exploring Viral Phylogeny for Engineered Optimized **Gene Delivery Vectors**

- Implementing large-scale sequence search algorithms to identify candidate virus proteins in deep sequencing databases
- Building gene delivery vectors from these naturally occurring viruses and testing them in vitro and in vivo for specificity and efficiency of gene delivery in various cell types
- Using this technology for in vivo targeted gene delivery of TCRs and CARs to treat oncology and autoimmune indications

David Johnson, Founder & Chief Executive Producer, GigaMune

12.30 Post-Infusion Control Features for Ex Vivo and In Vivo **Engineered CAR Immune Cells**

- The OmniCAR technology can be incorporated into exvivo or in vivo engineered CAR immune cells such as T-cells, NK, Macrophages, Gamma/Delta T, CAAR-Ts, and CAR-Tregs
- · Post-infusion control features such as the ability to turn the system on/off and back on again; to re-direct the immune cells from one target to any other; and the ability to multiarm cells against more than one target are increasingly important for safety and efficacy
- These features can all be incorporated into a single master cell or vector/method which can be used for any target and in any indication reducing manufacturing costs and streamlining the regulatory filing process

Daniel Shelly, Vice President, Business Development & Alliances. Prescient Therapeutics

1.00 Lunch Break

2.00 Return to Afternoon Plenary Sessions

Lots of new innovation and maturation of existing technologies and strategies for cell therapy were presented, very helpful

& Chief Operating Officer, Affylmmune

Eric von Hofe, President

Good value, relevant content and useful network with companies really active and relevant for the space

Helen Tayton-Martin, Chief Business Officer, Adaptimmune **Therapeutics**



REGISTER NOW

PRICING &

TRANSLATION TRACK

MORNING SESSIONS

Chair: Shannon Dahl, Industry Expert

Leveraging Dual Targeting to Improve Therapeutic Efficacy

& Safety
11.00 Novel Engineering Platforms for CAR-T Cell Signaling

Coopting proximal signaling molecules enables unique CAR-T

Studying T-cell signaling networks reveals CAR biology

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150



MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES

PRICING & DISCOUNTS



cell engineering Great speakers with a broad range of experience and lots of Developing logic-gated CAR-T cell platforms Robbie Majzner, Assistant Professor of Pediatrics, Stanford time to meet and network **University School of Medicine** Sven Kili, Chief Executive Officer, Antion Biosciences 11.30 Title TBC · Session details to be announced 12.00 Utilizing & Overcoming Antigen Escape in Leukemia CARs Reviewing antigen escape (expansion of cells not expressing taraet protein) Developing a non-gene edited CAR for T-ALL, as non CD7 heathy cells can rapidly expand Developing a combination CAR to overcome antigen escape Comprehensive. Exceptionally well organized and good quality in AML Greg Deener, Chief Executive Officer, iCell Gene Therapeutics content 12.30 Synthetic Immune Receptor, A Next Generation CAR-T Platform Samik Basu. Chief Scientific Officer & Vice President. Preclinical & • Introducing SIR, a next generation HLA-independent TCR platform that provides physiological TCR signaling Translational Research, Cabaletta Bio Describing the activity of SIR against blood cancers and solid tumors · Describing bispecific and multispecific targeting using SIR-T Preet Chaudhary, Professor & Chief of Hematology; Founder, **University of Southern California; Angeles Therapeutics** 1.00 Lunch Break 2.00 Return to Afternoon Plenary Sessions

44 www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com 📊 Cell Immunotherapy 🍏 @CAR_TCell 🕒 Preview the Event



MORNING SESSIONS

Chair: David Fontana, Chief Operating Officer,

Umoja Biopharma Sharing Clinical Results & Strategy for Solid Tumor

Treatments

Characteristics on the Clinical Outcome of Autologous TCR-T

11.00 Understanding the Impact of Patient & Product

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2


CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES

PRICING & DISCOUNTS





EARLY-STAGE CLINICAL STRATEGY TRACK

15 www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com 📊 Cell Immunotherapy 🍏 @CAR_TCell 🕑 Preview the Event



August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES

> PRICING & DISCOUNTS



TRACK MORNING SESSIONS Chair: TBC **Optimizing Cell Therapy Clinical Trial Design 11.00** Clinical Trials in the Age of Cell Therapy Designing clinical trials of autologous CAR-T and TCR therapeutics has unique requirements for which there is little prior experience Cross-sectional look at the cell therapy industry as a whole. I · Using adaptive trial designs can shorten dose-finding and speed up establishment of an optimal dosing schedule was impressed from start to finish Expanding indications to areas outside of oncology may require development of adequate placebo controls Miloš Miljković, Chief Medical Officer, Cartesian Therapeutics Damien Fink, Director, Analytical Development, Century **Therapeutics** 11.30 Study Design & Clinical Dose Escalation Data from ANTLER Phase 1 Trial for CB-010, an Allogeneic Genome-**Edited Anti-CD19 CAR-T Cell Therapy** Utilizing chRDNA genome-editing technology to develop Good conference, good energy, cross-functional topics armoring strategies that improve antitumor response in allogeneic CAR-T cell therapies · Designing early-stage clinical trials for allogeneic CAR-T cell Arvind Natarajan, Vice President, CMC & Process Development, therapies • Reporting safety and efficacy dose escalation data from the lovance ongoing CB-010 ANTLER Phase 1 trial Enrique Zudaire, Senior Vice President, Translational Sciences & Therapeutics Discovery, Caribou Biosciences

12.00 Group Discussion Session

12.30 Group Discussion Session

1.00 Lunch Break

2.00 Return to Afternoon Plenary Sessions

CLINICAL OPERATIONS



MANUFACTURING TRACK

Boston, MA

August 29 - September 1, 2023

MORNING SESSIONS

Chair: Sanjin Zvonić, Senior Vice President, Business **Development & Practice Expert, Dark Horse Consulting**

Aligning Manufacturing Capacity to Patient Demand

11.00 Optimizing Allogeneic Cell Therapy Manufacturing **Processes**

- · Design and scaling up of a fully non-viral allogeneic platform to clinical scale and beyond
- · Producing highly desirable Tscm cells with high yield, purity, and robustness
- · Continuously improving productivity and flexibility of process

Nooshafarin Sanaie, Vice President, Process & Analytical Development, Poseida Therapeutics

11.30 Novel Isolation & Activation Platform with Active-Release Technology for Scalable Cell Therapy Manufacturing

- CTS[™] Detachable Dynabeads[™] build upon Dynabeads[™] and CaptureSelect[™] technologies with an active release mechanism for clinical/GMP space
- CTS[™] Detachable Dynabeads[™] CD3/CD28 Kit shows >98% isolation efficiency, cell viability >90%, and CD25 activation >95%
- Studies show our CD4 and CD8 versions have efficient isolation, high cell recovery, and low non-target impurities

Eugene Kang, Senior Product Manager, Thermo Fisher Scientific

12.00 Moving Towards Feeder-Free iPS/ES-Derived Cell Manufacturing in Scalable Single-Use-Bioreactor

- · Generating unlimited numbers of hematopoietic organoids capable of producing innate killer cells in bioreactor at industrial scale
- Harvesting CD8+ ProtoNK with natural effector phenotype and consistent killer activity
- Optimizing downstream processes, maximizing in vivo target killing

Allen Fena, Founder & Chief Scientific Officer, HebeCell

12.30 CAR-T Cell Expansion Platforms Generate Distinct T **Cell Differentiation States**

- We compared 4 commonly used CAR-T cell manufacturing platforms (CliniMACS Prodigy, Xuri W25 rocking platform, G-Rex gas-permeable bioreactor, static bag culture) using identical media, stimulation, and donor starting material.
- · There were considerable differences in the output CAR-T cell phenotype, with the Prodigy significantly enriched for stem/ central memory-like (Tscm-like) T cells, while the bag and G-Rex cultures were more enriched for effector memory T cells. Expansion protocols were based on phase I/II clinical trials at the NIH Clinical Center.
- By analyzing differences among the platforms, we identified key physical differences that promote a more naïve/Tscmlike differentiation state in the Prodigy and have further identified a method by which Tscm-like cells can be enriched in multiple bioreactor platforms

Hannah Song, Product Development, NIH Clinical Center, **Center for Cellular Engineering (CCE)**

1.00 Lunch Break

2.00 Return to Afternoon Plenary Sessions

Overall great event with good opportunity for learnings of what others are doing in the community and opportunity for networking. Event staff were friendly and helpful and the event was very well organized

Michelle Andraza, Senior Associate Director, CMC, Global Ouality Assurance, **EXUMA Biotechnology**

> PRICING & DISCOUNTS



hansonwade

REGISTER IN ADVANCE TO CAR-TCR **SAVE \$150**

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING **DIVERSITY AT** CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP **OPPORTUNITITES**

August 29 – September 1, 2023 Boston, MA



REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST A MEETING

SPEAKERS

AGENDA AT A GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING DIVERSITY AT CAR-TCR

CONFERENCE DAY 1

CONFERENCE DAY 2

CONFERENCE DAY 3

PARTNERS

PARTNERSHIP OPPORTUNITITES

PRICING & DISCOUNTS



hansonwade

MORNING SESSIONS Chair: Emily Lowe, Senior Director, Head of Analytical Development, Appia Bio Ensuring Satisfactory Product Integrity with Improved **Release Testing Strategies** 11.00 Safety Strategy for iPSC-derived Allogeneic Cell Therapy **Drug Product Release** Leveraging non-clinical data to inform drug product release strategy · Identifying informative variant class assessments at each manufacturing stage Selecting appropriate methods for genetic characterization Damien Fink, Director, Analytical Development, Century Therapeutics 11.30 Critical Considerations in the Aseptic Manufacture of CAR-T **Cell Products** · CAR-T products require sterile manufacturing using specialized aseptic processing procedures. Final products must pass sterility testing and meet appropriate microbiological quality standards. While the pharmaceutical industry has a rich history of producing sterile drugs, aseptic processing for CAR-T cells is still evolving This presentation will cover vital aseptic processing procedures applied to CAR-T products, including current techniques and regulatory requirements. The speaker will draw from scientific literature, regulatory guidance, and consulting group experiences to provide insights into CAR-T product manufacturing Andrew Trammel, Director, Regulatory Sciences, Cardinal Health 12.00 Adapting Analytical Control Strategies to Rapid **Evolution of Cell Therapies** · Defining analytical methods for each component of cell therapy products • Utilizing phase appropriate validation of methods for release and characterization Discussing method transfers, comparability, and lifecycle management Shibani Mitra-Kaushik, Head, Product Control Strategy & Analytics, Takeda **12.30** Group Discussion Session 1.00 Lunch Break 2.00 Return to Afternoon Plenary Sessions

A very engaging and interactive program that allowed for learning new developments in the field and to connect with others involved in the area. Relevant topics, high quality speakers, opportunity to network.

CMC & ANALYTICS TRACK

Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics

It was a very good meeting with excellent talks.
Aishwarya Sathyanarayan, Senior Scientist, Process Analytical Development, Poseida Therapeutics

48 www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com ከ Cell Immunotherapy 🄰 @CAR_TCell 🕑 Preview the Event

August 29 - September 1, 2023 Boston, MA

> SUPPLY CHAIN & LOGISTICS TRACK



REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST

A MEETING

SPEAKERS

AGENDA AT A

GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING

DIVERSITY AT

CAR-TCR

CONFERENCE DAY1

CONFERENCE

DAY 2

CONFERENCE

DAY 3

PARTNERS

MORNING SESSIONS

Chair: Lee Buckler, Senior Vice President, Advanced Therapies & Business Development, Blood Centers of America

Enabling Stable & Secure Cell Storage & Delivery Through **Biopreservation & Cryopreservation**

11.00 Overcoming Cell Therapy Formulation Challenges

- Discussing cell therapy formulation challenges and potential solutions to overcome negative impact of cryopreservation on drug product CQA
- · Optimizing cryopreservation process based on drug product presentation and batch size
- · Assessing the impact of cryopreservation on post-thaw drug product quality

Lavanya Peddada, Director, Drug Product Development, **Century Therapeutics**

11.30 Innovative Biopreservation Solutions for Cell-Based Therapy

- Discovering how chemically-defined cryopreservation solutions can address gaps of conventional biopreservation approaches
- Understanding when cold storage can be a suitable alternative to cryopreservation
- · Exploring how custom solutions with recombinant human albumin support post-thaw cell viability

Rukmini Ladi, External Collaborations Manager CCT, Sartorius

12.00 Cellular Therapy Cryopreservation: Considerations for **Overcoming Cell Batch Variability (Virtual Presentation)**

- Developing an analytical method suitable for characterizing and testing cell therapy products
- Understanding the impact of a controlled rate freezing device on cell batch variability
- Considering the impact of transient warming events on the storage stability of cellular products

Olga Mykhailova, Scientist II, Cryopreservation, Process Development BlueRock Therapeutics

12.30 Group Discussion Session

1.00 Lunch Break

2.00 Return to Afternoon Plenary Sessions

Extremely enjoyable and a valuable experience. The quality of the talks was exceptional and the opportunity to network was extremely valuable. Marc Davies, Vice President, CAR Engineering,

Leucid Bio

Very glad I went. I learned several ideas and met new colleagues for potential collaborations.

Marie Koren-Gluzer, Associate Director, Cell Therapy, AstraZeneca



PARTNERSHIP **OPPORTUNITITES**

PRICING & DISCOUNTS





August 29 - September 1, 2023 Boston, MA



COMMERCIALIZATION & MARKET ACCESS TRACK

REGISTER IN ADVANCE TO SAVE \$150

WELCOME

MORE THAN JUST

A MEETING

SPEAKERS

AGENDA AT A

GLANCE

WORKSHOP DAY

FOCUS DAY

DISCUSSING **DIVERSITY AT**

CAR-TCR

CONFERENCE DAY1

CONFERENCE DAY 2

CONFERENCE DAY 3

MORNING SESSIONS

Chair: Renaud Vaillant, Founder & Chief Executive Officer, Alaya.bio

Attracting Investors to Improve Speed to Clinic & Commercialization

11.00 Panel Discussion: Entrepreneurs & Investors Discuss...

- What do investors look for in a company and product?
- Why would someone decide against investing? (i.e., key issues seen)
- Where do investors see cell therapy in 5 years?

Noelle Hutchins, Investment Associate, Omega Funds Justin Zelin, Director & Senior Biotechnology Analyst, BTIG Sahil Chopra, Vice President, Investments, Vertex Ventures

11.30 Elevator Pitch Session

- Presentation 1: ML Guide Library vs Library Screens: From Discovery to Clinic
- Presentation 2: Session details to be announced

Elizabeth Wood, Founder & Chief Executive Officer, JURA Bio

12.00 Panel Discussion: Giving Feedback on Elevator Pitches

- · Pitch your company/product to a panel of investors for feedback
- · Asking them questions that you would ask in a real-life scenario

Noelle Hutchins, Investment Associate, Omega Funds

Justin Zelin, Director & Senior Biotechnology Analyst, BTIG Sahil Chopra, Vice President, Investments, Vertex Ventures

12.30 End of Track

1.00 Lunch Break

2.00 Return to Afternoon Plenary Sessions

The 7th CAR-TCR Summit 2022 was the best one so far! The perfect combination of crowd, talks and vendors to do high quality networking! A must go meeting if you work in cell therapy

Erika von Euw, Vice President, Discovery & Translational Research, Deverra Therapeutics

Great event. Excellent and enjoyable. Karen Wen, Chief Strategy Officer, Genome Frontier



PARTNERSHIP **OPPORTUNITITES**

PARTNERS

PRICING & DISCOUNTS




hansonwade

August 29 – September 1, 2023 CAR-TCR Boston, MA

REGISTER IN ADVANCE TO SAVE \$150

hansonwade





August 29 - September 1, 2023 CAR-TCR Boston, MA



REGISTER

NOW

hansonwade



Partners

August 29 – September 1, 2023 Boston, MA REGISTER IN ADVANCE TO SAVE \$150





) C

معم

hansonwade

READY TO REGISTER?

Team Discounts

- 3 Passes 10% Discount
- 4 Passes 15% Discount
- 5+ Passes 20% Discount

Group discounts cannot be used in conjunction with any other or visit the website. Full T&Cs apply.

Secure Your Place Now

August 29 - September 1, 2023 **CAR-TCR** Boston, MA

Data Protection: The personal information shown and/or provided by you will be held in

Sometimes your details may be obtained or made available to third parties for marketing

a database. It may be used to keep you up to date with developments in your industry.

purposes. If you do not wish your details to be used for this purpose, please write to:

Database Manager, Hanson Wade, Eastcastle House, 27/28 Eastcastle Street, London



CONFERENCE

DAY1

CONFERENCE

DAY 2

CONFERENCE

DAY 3

PARTNERS

Drug Developer Pricing*	Register Online	On the Day Rate	WELCOME
Conference + (Workshop Day OR Bootcamp OR Focus Day)	\$5,399	\$5,549	MORE THAN JUST
Conference + 1 Workshop	\$4,949	\$5,099	A MEETING SPEAKERS
Conference Only	\$4,499	\$4,649	AGENDA AT A GLANCE
Start-Up Pricing**	Register Online	On the Day Rate	WORKSHOP DAY
Conference + (Workshop Day OR Bootcamp OR Focus Day)	\$3,999	\$4,149	FOCUS DAY
Conference + 1 Workshop	\$3,699	\$3,849	DISCUSSING DIVERSITY AT CAR-TCR

*Must be from a biotech or pharma company that is currently and publicly developing an in-house cell therapy to be eligible for this price

**Must be from a biotech company with less than 50 full-time employees that is currently and publicly developing an in-house cell therapy to be eligible for this price. This is also available for academics and not-for-profit organizations.

Do you work for a Service/Solution Provider or Vendor? Email us at sponsor@hansonwade.com to enquire about attending

VENUE

TERMS & CONDITIONS

made at any time.

Hynes Convention Center Hynes Convention Center, 900 Boylston St,

Boston, MA 02115 United States https://www.signatureboston.com/hynes/

3 Easy Ways To Book

Full payment is due on registration. Cancellation and Substitution Policy:

Cancellations received 14 days or less (including the fourteenth day) prior to the

Cancellations must be received in writing. If the cancellation is received more than 14

days before the conference attendees will receive a full credit to a future conference.

conference will be liable for the full fee. A substitution from the same organization can be

www.car-tcr-summit.com/take-part/register/

disputes, terrorism or hostilities.

Email: register@hansonwade.com Tel: +1 617 455 4188

PARTNERSHIP **OPPORTUNITITES**

ansonwade

PRICING & DISCOUNTS



www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com 📊 Cell Immunotherapy 🍏 @CAR_TCell 🕑 Preview the Event 55

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to

right to amend or cancel any event at any time. Hanson Wade is not responsible for any

loss or damage or costs incurred as a result of substitution, alteration, postponement or

cancellation of an event for any reason and including causes beyond its control including

without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial

content, speakers, date, timing, format and/or location of the event. We reserve the

the event programme as advertised. However, it may be necessary to alter the advertised

W1W 8DH